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The coupling of efficient separations and mass spectrometry 
instrumentation is highly desirable to provide global proteomic analysis. When 
quantitative comparisons are part of the strategy, separation and analytical 
methods should be selected, which optimize the isotope labeling procedure. 
Enzyme-catalyzed 18O labeling is considered to be the labeling method most 
compatible with analysis of proteins from tissue and other limited samples. The 
introduction of label at the peptide stage mandates that protein manipulation 
be minimized in favor of peptide fractionation post-labeling. In the present 
study, forward and reverse 18O labeling are integrated with solution isoelectric 
focusing and capillary LC-tandem mass spectrometry to study changes in 
mitochondrial proteins associated with drug resistance in human cancer cells.  
A total of 637 peptides corresponding to 278 proteins were identified in this 
analysis. Of these, twelve proteins have been demonstrated from the forward 
and reverse labeling experiments to have abundances altered by greater than 
a factor of two between the drug susceptible MCF-7 cell line and the MCF-7 
cell line selected for resistance to mitoxantrone. Galectin-3 binding protein 
precursor was detected in the resistant cell line, but was not detected in the 
drug susceptible line. Such proteins are challenging to 18O and other isotope 
strategies and a solution is offered, based on reverse labeling. These twelve 
proteins play a role in several pathways including apoptosis, oxidative 
phosphorylation, fatty acid metabolism and amino acid metabolism. For some 
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Chapter 1:  Introduction 
Part A 
Drug resistance in cancer chemotherapy 
Cancer is the second leading cause of death among all ages in the United 
States. Scientists are exploiting all ways to prevent, detect, diagnose and treat 
the disease. Surgery and radiotherapy cures about 40% of all cancer patients, 
leaving the remaining to rely on systemic chemotherapeutic treatment (1). 
Chemotherapy, which was introduced into the clinic more than fifty years ago, 
is an approach to cancer treatment that uses drugs to stop the growth of 
cancer cells either by killing the cells or by stopping the cells from dividing (2). 
 In reality, the effectiveness of chemotherapy has suffered from a range of 
puzzling factors including systemic toxicity and drug resistance. The latter 
problem has been the least understood and presents major obstacles to the 
successful treatment of tumors. Drug resistance can be either intrinsic or 
acquired. Intrinsic resistance results in failure to respond to the first 
chemotherapy which is given to patients. Acquired resistance occurs in 
successive treatments following initial response (2-5). When tumor cells 
develop resistance, they become resistant to not only the drug with which the 
patient has been treated but also to a broad spectrum of structurally and 
functionally unrelated drugs, in a phenomenon referred to as multidrug 
resistance (MDR). Clearly, if drug resistance could be overcome, the impact on 
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survival would be highly significant. 
A variety of mechanisms at molecular and cellular levels for MDR have 
been intensively studied since the seventies (6-10). They include reduced drug 
accumulations by enhancing efflux of anti-cancer drug from the cell or 
preventing drug influx, increasing activity or expression of detoxifying systems, 
disruptions in the apoptotic pathway, alterations in the drug targets, 
up-regulation of DNA repair systems. 
The major mechanism of multidrug resistance is the alteration in drug 
efflux due to overexpression of ATP-binding cassette (ABC) transporter 
proteins such as P-glycoprotein (P-gp) and multidrug resistance protein (MRP) 
(4, 8, 11). P-gp acts as a plasma membrane drug efflux pump that actively 
exports drugs from cancer cells, thereby allowing the cell to accumulate fewer 
drugs and thus survive higher doses. The normal function of MRP has been 
identified as a carrier of negatively charged natural-product drugs. This has led 
to the development of P-gp or other ABC transporter inhibitors in clinical 
treatment to restore, enhance or prolong drug sensitivity (12). Another 
important ATP binding cassette family member is breast cancer resistance 
protein (BCRP), which has been discovered in the breast cancer cell lines 
resistant to mitoxantrone, daunorubicin and doxorubicin, etc (13).  
Another mechanism of MDR which has been well studied is the alteration 
in the amount, structure or activity of molecular targets (2, 6). A typical example 
for such target-related MDR is resistance to topoisomerase II (Topo II) 
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inhibitors and poisons. DNA topoisomerases are essential enzymes which are 
involved in the processes of replication and transcription by binding to DNA, 
forming a transient DNA break followed by DNA strand passage and then 
releasing the DNA. A class of anticancer drugs (e.g., mitoxantrone, doxorubicin 
and others) targets these topoisomerases to kill tumor cells. These drugs 
prevent the releasing process by freezing and accumulating the cleavable 
DNA-enzyme complexes, leading to cell death. Clinical studies have shown an 
association between low cellular levels of Topo II and poor treatment 
outcomes.  
Numerous studies to date strongly suggest that most forms of 
chemotherapy kill cancer cells by inducing them to undergo apoptosis (14, 45). 
Thus an important mechanism which can prevent cancer cells from dying, 
despite adequate drug-induced damage at the molecular target, is the 
processes that block apoptosis (15-17). For example, functional loss of p53, 
which is a critical initiator of the apoptosis pathway, correlates with multidrug 
resistance in many tumor types (6). Also, mutations or altered expression of 
Bcl-2 related proteins are associated with drug resistance in human cancers 
(18-20). 
To date the mechanisms of drug resistance are poorly understood. They 
are likely to be multifactorial and complex in most cancer patients (7-8). Many 
proteins are involved and work together to confer and promote drug resistance. 
Understanding the causes could improve the efficiency of existing therapies 
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and potentially reveal new treatment strategies. Even though previous studies 
have suggested that many proteins such as P-gp, MRP and Bcl-2, are 
differentially expressed in drug-resistant tumor cells, global protein pattern 
changes in these tumor cells have not yet been determined. With recent 
developments in mass spectrometric and separation technologies, along with 
genomic and protein bioinformatics, the complex status of protein expression, 
structure and function, defined as proteomics, can be analyzed. The 
proteomics approach has provided a powerful tool to study drug resistance. 
Mitochondria and cancer chemotherapy 
Owing to the complexity of human cells, in order to assemble a list of the 
total complement of proteins in the cells, proteomic studies of subcellular 
compartments and organelles has become a major focus (21-22). Thus 
smaller and more manageable subsets of proteins are involved. In this study, a 
proteomic analysis of mitochondrial fraction has been used to study alterations 
in the protein abundance profile between drug susceptible and drug resistant 
human MCF-7 breast cancer cells. 
The mitochondrial genome encodes only 13 polypeptides. Therefore the 
vast majority of mitochondrial proteins are encoded by the nuclear genome, 
synthesized in the cytosol, and then imported into mitochondria by a specific 
transport system (23-24). The number of distinct proteins in human 
mitochondria is estimated to be approximately 2000 (24-25). 
Mitochondria are attractive targets for subcellular proteomics because 
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they play vital roles in several cellular functions, including energy production by 
oxidative phosphorylation, fatty acid metabolism, citric acid cycle and 
programmed cell death (apoptosis) (26-28).  
In the last decade, there has been a surge of interest in investigating the 
mitochondrial role in apoptosis. Apoptosis is defined as genetically 
programmed autonomous cell death. It occurs in healthy cells at varying rates 
(46). Changes in the genetics of apoptotic regulation may result in an increase 
in cell numbers, which begins the process of tumorigenesis (47). There are two 
major apoptosis pathways, intrinsic and extrinsic, in mammalian cells. Both of 
them are mediated through the mitochondria, as seen in figure 1 (29). The 
extrinsic pathway is triggered by members of the death receptor superfamily, 
such as CD95. Binding of CD95 ligand to CD95 results in receptor clustering 
and formation of a death inducing signaling complex (DISC). This complex 
recruits multiple procaspase-8 molecules via the adaptor molecule 
Fas-associated death domain protein (FADD), which will then rapidly activate 
the initiator caspase 8. The intrinsic pathway occurs when various 
stress-induced apoptotic stimuli, including DNA damage that results from 
chemotherapy, trigger the release of cytochrome c from mitochondria. The exit 
of cytochrome c is regulated partially by Bcl2 family members, with 
anti-apoptotic (e.g. Bcl2) and pro-apoptotic (e.g. Bax, Bak) members inhibiting 
or promoting the release, respectively. Cytochrome c then interacts with 
apoptotic protease-activating factor 1 (Apaf1) and caspase-9 to form the 
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“apoptosome complex”, resulting in activation of the initiator caspase-9. The 
extrinsic and intrinsic pathyways converge at the level of caspase cascade (e.g. 
caspase-3, 6, 7) activation, which is induced by caspase-8 or 9. Those 
caspase cascades are responsible for the cleavage of important cellular 
substrates leading to cell death (30-33). 
Because the importance of mitochondrial dysfunction during apoptosis 
induced by anticancer drugs has been illustrated (41-42) and preventing 
apoptotic death process contributes to drug resistance (15-17), mitochondrial 
targeting strategies have become a unique potential for the design of 
anticancer drugs (17, 34). For example, the antitumoral drug Lonidamine, 
which is used in combination with standard chemotherapy, induces apoptosis 
via a direct effect on mitochondria by disrupting the mitochondrial 
transmembrane potential, thus helping release of cytochrome c (35-36).  All 
of the evidence support our rationale that information about mitochondrial 
proteins, identified or quantitated by proteomics, could provide insight towards 










Figure 1.  Intrinsic and extrinsic pathways of apoptosis (33)  
There are intrinsic and extrinsic apoptosis pathways in mammalian cells. Both 
of them are mediated through the mitochondria. Triggering of cell surface 
death receptors including CD95 results in rapid activation of the initiator 
caspase 8 after its recruitment to a trimerized receptor-ligand complex (DISC) 
through the adaptor molecule Fas-associated death domain protein (FADD). In 
the intrinsic pathway, stress-induced apoptosis results in perturbation of 
mitochondria and the ensuing release of proteins, such as cytochrome c. The 
release of cytochrome c is regulated in part by Bcl2 family members. Once 
released, cytochrome c binds to apoptotic protease-activating factor 1 (Apaf1), 
which results in formation of the Apaf1–caspase 9 apoptosome complex and 
activation of the initiator caspase 9. The activated initiator caspases 8 and 9 
then activate the effector caspases 3, 6 and 7, which are responsible for the 
cleavage of important cellular substrates resulting in the apoptotic phenotype. 
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MCF-7 cells as a model system 
In the present study, a comparative proteomic study has been carried out 
between a drug-susceptible MCF-7 human breast cancer cell line (parental cell 
line) and the MCF-7 cell line that has been selected for resistance to 
mitoxantrone. 
The MCF-7 cell line was derived in 1970 from the pleural effusion of a 
patient with metastatic breast cancer (37). The cell line is one of the most 
widely used cell lines in laboratories as an investigative tool because of 
multiple characteristics, including its stability (38).  
The drug resistant cell line used in this study is the mitoxantrone resistant 
MCF-7 cell line (MCF-7/MX). Mitoxantrone is commonly used in treatment of 
leukemia, lymphomas and breast cancer (40). The structure of this drug is 
shown in figure 2, which is a synthetic anthraquinone. The exact mechanism of 
its action is unknown but includes intercalation with DNA to cause inter- or 
intra-strand DNA cross-linking. It also inhibits DNA topoisomerase II. All these 
prevent DNA synthesis and repair, thus leading to cell death (43-44). 
Furthermore, since mitoxantrone contains a quinine functional group in its 
structure it has been considered to undergo activation by metabolic reduction 
(48). Quinones can undergo reduction to form semiquinone radicals, which 
can produce various reactive oxygen species (ROS), such as hydrogen 
peroxide, in the presence of molecular oxygen. This may ultimately lead to 




   












             
Figure 2. Mitoxantrone structure 
 10
some production of ROS by mitoxantrone (49).  MCF-7/MX cells, which were 
provided by Dr. Ken Cowan at National Institutes of Health, were isolated by 
serial passage of the parental MCF-7 cells in stepwise increasing 
concentrations of the mitoxantrone (39). MCF-7/ MX cell line is approximately 
4000-fold more resistant to mitoxantrone, and also 10-fold cross-resistant to 
doxorubicin and etoposide. The most well defined mechanism for resistance 
has been associated with enhanced drug efflux due to overexpression of a 
characterized ATP-binding cassette transporter protein, BCRP (50). 
It was known that mitoxantrone damages the mitochondrial membrane 
and mitochondrial energy metabolism (51-52). In addition, mitoxantrone can 
cause mutation and loss of mitochondrial tDNA (mtDNA) (53). Collectively, 
mitochondria may play a role in mitoxantrone function, as well as the process 
of mitoxantrone-resistance process. 
Part B 
Proteome and Proteomics 
The human genome has been completely sequenced, and 20,000~25,000 
protein-encoding genes have been identified (54). However, researchers are 
realizing that much of the complexity of the human organism and biological 
function must rely on the proteins these genes encode—the “proteome” 
(56-58). The proteome, which was first coined in 1995, was defined as the 
time- and cell-specific protein complement of the genome (55). The expressed 
products of a single gene in reality represent a protein population, which may 
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be regulated at the level of translation, or more often, the accumulation, 
degradation and posttranslational modification during biological processes. 
Protein expression is also dynamic in response to external and internal stimuli 
such as pathological, pharmacological and aging conditions (59). With 
accumulating evidence that mRNA levels frequently do not reflect the protein 
levels (57-58), proteomics has become a systematic and indispensable 
discipline for separating and “visualizing” the protein components within a cell. 
These include the study of proteins, protein levels, protein-protein interactions, 
protein modifications of an organism. One of the most interests in proteomic 
application is disease investigation including development of novel biomarkers 
for diagnosis, identification of new therapeutics targets (60-62).  
The number of different protein molecules in a mammalian organism 
ranges from 1 million to 20 million (63). Moreover, the dynamic range of protein 
abundance in biological samples can be as high as 106 (64). These 
complexities require the development of rapid and easily utilized analytical 
techniques, among which, mass spectrometry has been the most powerful tool 
in proteomics. 
 
Principles of mass spectrometry in proteomics 
Mass spectrometry measures the masses of individual molecules and 
atoms. The first essential step in mass spectrometry analysis is to convert the 
analyte molecules into gas-phase ionic species in the ionization source. The 
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excess energy transferred to the molecule during its ionization process will 
lead to fragmentation of that molecule. Next, a mass analyzer separates these 
molecular ions or their charged fragments according to their m/z (mass over 
charge) ratio. Finally, the number of ions at each m/z value are detected by a 
suitable detector and displayed in the form of a mass spectrum.  
Since the 1990s, mass spectrometry has undergone tremendous 
technological improvements, which made it applicable to proteins, peptides 
and other biological related molecules. Among them, electrospray ionization 
(ESI) and matrix-assisted laser desorption ionization (MALDI) are now the 
most common ionization sources for biomolecular mass spectrometry (65). 
They are also referred to as “soft” ionization because they can generate ions 
from nonvolatile macromolecules such as proteins and peptides without 
significant fragmentation and even maintain noncovalent interactions under 
some specific conditions.  
Electrospray ionization (ESI) mass spectrometry was developed by Fenn 
and co-workers in the 1980s (66). In ESI, the sample solution containing a 
protic primary solvent is sprayed from the tip of a metal nozzle under a strong 
electric field. The solution is then dispersed into a find spray of charged 
droplets. Either heat or dry gas is applied to the droplets at atmospheric 
pressure, causing the solvent to evaporate from each droplet. The charge 
density on its surface increases as the size of the charged droplet decreases, 
leading to multiple charged analyte ions. Thus very large molecules (up to 
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70,000 Da) could be detected by mass analyzers with a relatively small mass 
range, because mass spectrometry measures the mass-to-charge ratio (m/z). 
Another advantage of ESI, which made it immediately popular, is that it could 
be interfaced with liquid-based (e.g. chromatographic and electrophoretic) 
separation tools. A variation of ESI was developed by Wilm and Mann (67), 
called nanospray (nanoESI). In this method, the spray needle has been made 
very small (flow rates are 10~100 nl/min) and is positioned close to the 
entrance to mass analyzer. The simple adjustment, however, increases 
sensitivity and efficiency dramatically.  
MALDI was first demonstrated for proteins in 1988 by Karas, Hillenkamp 
(68) and Tanaka (69). In MALDI analysis, the analyte is first co-crystallized with 
a large molar excess of a matrix compound, which is usually a UV-absorbing 
organic acid. Irridiation of this analyte-matrix mixture by a laser results in the 
vaporization of the matrix, which carries the analyte into gas phase. During the 
desorption process, the analyte molecules are protonated and form singly 
charged ions predominately. The efficient and direct energy transfer during 
MALDI ionization provides high sensitivity and a high mass range (up to 
300,000 Da). MALDI-MS is normally used to analyze relatively simple 
mixtures.  
As for mass analyzer, the three most commonly used analyzers are the 
ion trap, time-of-flight (TOF) and quadrupole. In the ion trap technique, the 
analyte ions are trapped in a region consisting of two end-cap electrodes and a 
 14
ring electrode under a variable radio-frequency voltage. Ions are then ejected 
separately from the ion trap to the detector when the radio frequency is 
scanned to resonantly excite the ions. Because the ions are all captured for a 
certain time interval before ejecting to detector, ion traps are very sensitive. 
The linear time-of –flight analyzer is the simplest analyzer. When a group 
of ions are given the same amount of energy through an accelerating poteintial 
and accelerated to a detector, the lighter and heavier ions reach the detector at 
different times. The different traveling times are dependent on the 
mass-to-charge ratios of different ions. TOF has a significant mass range 
which can be higher than 300,000 m/z. The time-of-flight analyzer is often 
coupled with a MALDI ionization source as shown in figure 3. 
The quadrupole mass analyzer selects ions by varying electric fields 
between four rods to permit a stable trajectory only for ions of a particular m/z 
value (70).  
The separated ions eventually impinge on a detector. The mass spectrum 
is a graph of signal intensity against the m/z value. It contains a series of peaks, 
each corresponding to a particular ion (e.g. peptide or protein), and peak 
heights that show the relative abundances of the ions. The ions in these peaks 
can be further fragmented to give a second mass spectrum, referred to as a 
tandem mass spectrum (MS/MS spectrum). One of the primary fragmentation 
processes is known as collision-induced dissociation (CID). CID is achieved by 
generating the ion of interest and selecting it with an analyzer. The ion then 
 15
collides with inert gas molecule, leading to the fragments, which are then 
analyzed as regular ions. In a multiple quadrupole mass analyzer, the 
subsequent MS/MS analysis is performed by consecutive analyzer. In an ion 
trap analyzer, however, MS/MS is performed with the same analyzer. Tandem 
mass spectrometry allows the analysis of a heterogeneous mixture of peptides, 
because each peptide can be selected for individual fragmentation. The 
fragment ions, referred to as product ions, can be separated into two classes 
(Figure 4). One class retains the charge on the N-terminal where cleavage 
occurs at one of three different positions. There are a-, b- and c- ions. The 
other class retains the charge on the C-terminal in ions formed by cleavage at 
three different positions, named as x-, y- and z- ions. Among these, b- and y- 
ions are the predominant ions in MS/MS spectra because the amide bond is 
most easily broken. The mass difference between two conjunct b- or y-series 
ions reflects the mass of an amino acid. 
The main instrument used for this thesis is a quadrupole time-of-flight 
mass spectrometer, which is shown in figure 5. The ESI quadrupole TOF 
combines the stability of a quadrupole analyzer with the high sensitivity and 

















    
 
   
 





Figure 5.  An electrospray ionization quadropole time-of-flight mass         
spectrometer 
The quadrupole TOF instrument combines quadrupole instrument with a TOF 
section for measuring the Mass of ions. Ion optics focuses the ions, Q1 is the 
first quadrupole for ion selection and Q2 is the second quadruple for collision 









Protein identification and bioinformatics 
Protein identification in proteomics refers to distinguishing different 
proteins by their different amino acid sequences. Conventional sequencing 
strategies include Edman degradation and de novo sequencing (71). In those 
methods, partial sequences are normally obtained either by automated, 
stepwise chemical degradation of proteins/peptides or fragmenting peptides by 
MS. These partial sequences were frequently used for the generation of 
probes for the isolation of the gene coding for the protein from a gene library 
(65). With the rapid improvement of high mass accuracy of MS and completion 
of sequencing of the human and many other genomes, high-throughput protein 
identification can be achieved by correlating mass spectrometric data with 
sequences in the databases with the aid of novel search algorithms.  
Two mass spectrometric methods are now widely used in protein 
identification: peptide mass mapping (peptide mass fingerprinting) and peptide 
tandem spectrometry. In peptide mass mapping, the protein of interest is either 
enzymatically or chemically cleaved and the resulting peptide masses are 
measured as accurately as possible in a mass spectrometer. The obtained 
“peptide mass fingerprint” of the protein is compared to calculated peptide 
masses obtained by theoretical cleavage of protein sequences stored in 
databases. In the comparison, one of those available computer algorithms, 
such as probability based matching (MASCOT) can be applied to assign a 
score to each match that ranks the quality of the matches (72-73). The 
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top-scoring candidate can be considered as the identified protein. It has been 
shown that only a small number of accurately measured peptide masses are 
required for unambiguous protein identification (74). This approach, however, 
requires a relatively purified target protein. Thus prior protein fractionation is 
often necessary.  
 Protein identification using tandem mass spectrometry is more specific 
than that achieved by peptide mass mapping, because the pattern of fragment 
ions in the MS/MS spectrum provides fairly unique sequence information about 
individual peptides from the peptide mixture. Those observed fragment ions of 
each peptide are matched against predicted fragment ions of all peptides 
derived from the proteins in the database using the computer algorithm. The 
best peptide and thus protein candidate can be determined. This approach can 
typically only require a single to at most several peptide MS/MS spectra to 
identify a protein from a complex mixture in a constrained database (75). In 
addition, it can be easily automated and can also be adapted to find peptides 
carrying specified post-translational modification by instructing the program to 
expect modifications at specific residues (76). 
Part C 
Separation of protein and peptide mixtures 
There are two important analytical problems existing in proteomics 
analysis: dynamic range of protein abundance and diversity of protein 
expression, such as multiple protein isoforms (59). Although mass 
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spectrometry including MS and tandem MS offers a powerful separation tool 
because individual peptide can be selected, isolated and sequenced among 
the co-detected peptides, to overcome these problems, one of two approaches 
is usually taken prior to mass spectrometry: 1) Proteins are prefractionated 
and the intact proteins are introduced into the mass spectrometer for protein 
identification and analysis (this may be characterized as “top-down” 
proteomics (77-79)); 2) A complex protein mixture is either separated first and 
then digested into peptides or first digested and then resolved ( both may be 
characterized as “bottom-up” proteomics and the latter one is often referred to 
as “shotgun” proteomics (80)). In both approaches, routine and reproducible 
separation or prefractionation techniques need to be developed. Distinct 
characteristics of proteins such as molecular weight, shape, solubility and 
hydrophobicity can guide the design of separation techniques. Figure 6 shows 
the general flow chart of proteome analysis including the commonly employed 
separation tools.  
1. Separation of a specific protein or a group of proteins 
Affinity liquid chromatography or capillary electrophoresis (CE) is effective 
method to specifically isolate and enrich specific target protein(s) (81). The 
principle of affinity columns is based on the ability of biologically active 
substances (affinant) to bind specifically and reversibly with complimentary 
substances (protein of interest). Those affinants attached to the surface of the 


































Figure 6.  Schematic of proteomic analysis 
 23
subjected to the column, the proteins of interest will be captured by the affinant 
and all the other molecules will pass through the column. The captured protein 
can later be eluted by changing the properties of the buffer, pH or temperature, 
etc. Many affinity columns are designed to isolate post-translationally modified 
proteins/peptides, which are normally present at very low abundance in 
complex mixture (82). For example, immobilized metal affinity columns (IMAC) 
loaded with Fe (III) or Ga (III) ions has been successfully used for the isolation 
of phosphorylated proteins/peptides (83-84). Immunoaffinity chromatography 
is another powerful technique for isolation of phosphorylated molecules (85). 
Glycoproteins, which also play an essential role in the protein functions and 
cellular processes, can be separated by lectin affinity or antibody 
chromatography (86). 
2. Multidimensional separations of proteins/peptides 
Resolving a complex mixture from a cell, tissue or organism can not be 
achieved by a single chromatographic or electrophoretic method. It is clear that 
multidimensional separation tools should be combined to fractionate proteins 
for mass spectrometric analysis.  
A. 2-D gel electrophoresis 
Two-dimensional gel electrophoresis (2-D gel), a technique 30 years old, 
is still the most used multidimensional separation technique for cell and tissue 
proteins. Proteins are separated in the first dimension by isoelectric focusing 
on an immobilized pH gradient strip and in the second dimension by their 
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molecular weights using sodium dodecylsulphate-polyacrylamide gels 
(SDS-PAGE). Inorganic or organic dyes such as silver stain and Commassie 
blue may be applied to visualize the proteins in 2D gel after separation. 
Individual protein spots on the gel can be excised and subjected to proteolytic 
digestion (usually trypsin). After that, the resulting peptides can be removed 
from the gel matrix and analyzed with subsequent peptide mass mapping or 
tandem MS, leading to protein identification and other characterization. 
Thousands of proteins including distinct post-translationally modified protein 
isoforms can be separated, visualized and quantitated in a single 2D gel run 
(58, 87). However, it is widely recognized that 2D gel method also suffers from 
several technical limitations. Specific classes of proteins, including proteins 
with extremes in pI, molecular weight, hydrophobicity, and low abundant 
proteins have been known to be excluded in 2D gel. In addition, 2D based 
methods are relatively tedious and time consuming. 
B. Multidimensional separations in-solution 
Alternative two-dimensional separation systems in solution (“gel-free” 
approaches) have emerged to interface protein and peptides separations 
directly to mass spectrometers. One of the most promising approaches is 
termed the “shotgun” technique. The components of a proteomic sample are 
digested with a suitable protease and the resulting peptides are resolved by 
multidimensional separation techniques, which employ a combination of two or 
more different separation steps before introduction into a mass spectrometer. 
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One advantage is that peptides are more soluble and easier to separate than 
the parent proteins. The disadvantage is that the increase in the number of 
peptides makes the sample mixture more complicated than the original protein 
pool, which must be overcome by subsequent high resolution and 
comprehensive analytical techniques. Currently in-solution separation 
strategies are based on two techniques: liquid chromatography (HPLC) and 
gel-free electrophoresis.  
B-1: HPLC separations 
High performance liquid chromatography is highly compatible with mass 
spectrometry and there is a broad selection of stationary and mobile phases, 
which makes LC a versatile and fundamental tool in proteomics. There are four 
main types of LC: reversed-phase, ion-exchange, affinity and size-exclusion 
chromatography. 
Currently, most LC separations in proteomics are achieved by 
reversed-phase partitioning HPLC (commonly termed reversed-phase HPLC 
or RPLC). Proteins/peptides stick to reverse phase HPLC columns in high 
aqueous (usually water) mobile phase and are eluted from the columns with 
continuously increased organic component such as acetonitrile, methanol in 
the mobile phase. Analytes are separated based on their hydrophobic 
characteristics. The least polar molecules are flushed out last. The specificities 
of HPLC columns are affected by the stationary phases, which are generally 
made up of hydrophobic alkyl chains that interact with the analytes. There are 
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three common chain lengths, C4, C8 and C18. The larger protein molecule will 
have more hydrophobic regions to interact with the column and thus a shorter 
chain length is more appropriate. So C8 and C18 are used for peptides while 
proteins are usually separated by a C4 column. 
To improve resolution, reversed phase HPLC is often coupled with 
another LC column(s) to give multidimensional separation. In these methods, 
ion-exchange chromatography is used most often as the first chromatographic 
dimension. 
Ion-exchange chromatography relies on charge-charge interactions 
between the sample and the functional charged sites immobilized on the resin. 
Ion-exchange chromatography can be classified into cation exchange 
chromatography, in which positive-charged ions bind to a negative-charged 
resin such as –SO3-H+ and anion exchange chromatography, where the 
binding ions are negative and the immobilized functional group such as 
–N(CH3)3+ OH is positive. The analytes are bound to the column with the 
starting buffer (e.g. NaCl) of low ionic strength, and then the bound molecules 
are eluted off using a gradient of a second buffer which steadily increases the 
ionic strength. Proteins/peptides with lower charge strength elute earlier. 
Each fraction from strong Cation-exchange chromatography is often 
directly coupled with reversed-phase LC-MS (on-line SCX-RPLC-MS). Yates 
and his co-workers (80, 88-89) have developed the multidimensional protein 
identification technology (MudPIT). In this approach, digested peptides from a 
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protein mixture are separated using a “mixed-bed” microcapillary column 
packed with moieties of strong cation-exchange and reversed-phase stationary 
phase, which are interfaced back to back (Figure 7). Peptide fractions were 
eluted from the SCX beads onto the reversed-phase material using a salt 
gradient. Between salt steps, an organic solvent gradient was used to elute 
peptides from the RP column into the electrospray MS. The MudPIT has 
emerged as an effective and robust tool.  
Affinity chromatography, as mentioned above, may also be combined with 
RPLC to study a particular set of proteins, such as low abundant 
post-translationally modified proteins/peptides, or to remove high-abundance 
components that mask other proteins (86, 90-91). For example, Apffel et al. 
interfaced concanavalin A affinity chromatography to reversed-phase RPLC in 
order to separate tryptic digests of serum glycoproteins prior to mass 
spectrometric detection (90).  
Size-exclusion chromatography (SEC) separates proteins and other 
biological macromolecules on the basis of their molecular size. The column is 
packed with small porous polymer beads designed to have pores of different 
sizes. As the analytes travel down the column some particles enter the pores. 
The larger the particles, the fewer pores can they enter. Thus they will have 
less overall volume to pass through, resulting in faster elution time. A few 











Figure 7.  Multidimensional protein identification technology (MudPIT) 
electrospray interface including a biphasic microcapillary column packed with 
strong cation-exchange and reversed-phase packing material (80). 
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Gao et al. use size exclusion to separate whole cell lysates, and following 
proteolysis of these fractions, each was separated by RPLC, which was 
coupled on-line via electrospray to an ion trap mass spectrometer (92). The 
smaller number of applications of SEC is due to its low resolution and limited 
loading capacity (82). 
B-2: Electrophoretic separations 
Electrophoresis separates proteins in an electric field based on the 
differences in their charge, or mass-to-charge ratio. There are gel-based 
(mentioned above in the 2D gel separation) and liquid-based systems that use 
this approach. Among the liquid-bases systems, capillary electrophoresis and 
solution isoelectric focusing are the most two promising methods in MS-based 
proteomics.  
i) Capillary electrophoresis (CE) 
CE separation depends on the different rates at which analyte ions 
migrate through narrow-bore capillaries under an electric field. The mobility of 
each ion is determined by its charge and size. It is well known that CE provides 
high speed and high resolution separation (95-97) of proteome-wide proteins 
and their peptides. There are two frequently applied modes in CE: capillary 
zone electrophoresis (CZE) and capillary isoelectric focusing (CIEF).  
Capillary zone electrophoresis is the simplest and most widely-used mode 
in CE. In CZE the cationic and anionic analytes are attracted towards different 
directions. However, they are all moving to the cathode because the 
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electroosmotic flow is usually significantly higher than the analyte velocity due 
to its electrophoretic mobility. Cations elute first because the direction of their 
migration is the same as the direction of EOF. Neutral molecules elute next 
without being resolved as they only move with EOF, while anionic analytes 
elute last. Among same-charge-sign ions, those with the highest charge/mass 
ratio will migrate first. 
CZE-MS has shown as a high efficient method in proteomics (98-100). 
However, the requirement for a background electrolyte in CZE results in a 
lower dynamic range of measurements than LC-MS (101). In multidimensional 
separations, CZE is often used as a final dimension before MS due to its fast 
separation and limited loading capacity (95). 
Capillary isoelectric focusing (CIEF) separates amphiprotic molecules 
based on differences between their isoelectric points (pI). CIEF is performed 
by filling the capillary with the sample and a mixture of carrier ampholytes with 
a certain pH range. An electric field is applied across the capillary with a basic 
solution at the cathode and an acidic solution at the anode. The molecules will 
then migrate to the point where their net charges are zero (pH=pI). As a result, 
analytes are separated into narrow zones of different pH through the capillary. 
CIEF-MS has been successfully applied to a number of complex 
proteomic systems (102-105). Larger loading capacity than CZE can be 
achieved, leading to good sensitivity and sample is concentrated in the 
process by a factor of two or three orders (102). But it was found that the 
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carrier ampolytes might interfere with MS interfacing (95). In multidimensional 
separations, CIEF is suitable to be the first dimension since it is an equilibrium 
technique. 
ii) Solution isoelectric focusing 
Methods of solution isoelectric focusing are electrokinetic strategies, 
which are performed in free solution relying on isoelectric focusing steps 
similar to CIEF. The applied devices include multichamber apparati, such as 
the multicompartment electrolyzer with immobilized membranes (MCEs) and  
rotationally stabilized focusing apparatus (Rotofor) (106).  
The Rotofor system has a long history in solution isoelectric focusing 
methodologies. It was developed by Bier (107). The Rotofor cell consists of a 
cylindrical focusing chamber that holds a plastic core dividing the chamber into 
20 compartments separated by polyester screens. The screens are resistant to 
fluid convection but they do not prevent the flow of current or the migration of 
proteins. Proteins and carrier ampholytes are loaded into the assembled 
chambers and then migrate in response to an electrical field to the 
compartments that are at pH values nearest to their pIs. The whole chamber 
rotates in order to avoid overheating and gravity effects during the separation 
process. Each fraction with narrow pI range can be subjected to further 
separation. Researchers have reported combining Rotofor separation with 
HPLC to analyze protein mixture (108-110). 
Righetti described a multicompartment eletrolyzer (MCE) where each 
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compartment is separated by a polyacrylamide gel membrane with a specific 
pH (111-112) maintained by immobilized ampholytes. Proteins/peptides in the 
solution are fractionated under an electric field by migrating into different 
compartments according to their pIs. That is, only peptides with pIs between 
the limited pH values of the boundary membranes remain in each chamber. 
Some advantages of such a separation will be: 1) the isoelectric membrane 
can be specially designed to select the pH range and degree of fractionation 
desired (113-115) 2) the chance of precipitation is small in solution 3) sample 
loading is quite flexible and even a peptide mixture with a large dynamic range 
is expected to be well separated and concentrated. The limitation is that 
automation is hard when MCE is coupled with other separation methods on 
line. This dissertation outlines a shotgun method with the combination of MCE 
in the first dimension and RPLC-MS as the second dimension for analysis of 
mitochondrial peptides. 
Part D  
Quantitation 
Although identification of proteins is often a necessary first step in 
proteomics approaches to elucidate protein function, measuring protein 
abundance levels is crucial to obtain a complete picture of many biological 
processes, and is referred to as quantitative differential proteomics. Cells are 
dynamic. The abundance of proteins within cells is not only regulated by 
transcription but also by translation and post-translation at events. Since 
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studies showed that there is no good correlation between mRNA quantities 
and protein quantities (116-118), globally profiling protein abundances 
becomes an essential part of proteomics. Previously, quantitative studies were 
limited to smaller numbers of proteins and were mainly dependent on the use 
of antibodies, which may be considered as “semiquantitative” because binding 
affinities of antibodies vary and antibodies against all proteins are not available 
(119). With well-established mass spectrometry and rapid methodological 
developments, large-scale quantitative proteomics strategies are able to 
produce numerous analyses that would have taken decades to measure with 
classical methods. 
1. Relative quantitation 
It is often not necessary to measure the absolute amount of protein 
present but rather to compare the relative abundances of proteins among 
related states. This is referred to as comparative proteomics (120-121). An 
important goal in this field is to provide a snapshot of protein expression within 
a cell in response to biological perturbations such as disease state, drug 
treatment, and aging (121) and thus understand the dynamics of living 
organisms. 
A. Gel-based methods 
For a number of years, comparative proteomic studies have been 
implemented by contrasting the position and intensities of protein spots among 
parallel gels derived from different samples. Computer software (e.g. 
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Compugen Z3) can make digitized images of the stained gel arrays and 
evaluate protein abundance changes by differential densitometry (122-123). 
Another approach involves labeling of two samples with two different 
fluorescent dyes (e.g. Cy-3 and Cy-5) and differentially imaging the fluorescent 
emission with optical filters (124-125). Although scanning of spots in 2-D gels 
is a straightforward process, which avoids possible downstream interference 
and is able to detect intact proteins and may distinguish protein isoforms (126). 
There still are some inherent problems in the method. For example, more than 
one protein might be present in a single spot. The cost of the dyes and the 
equipment used for visualization restrict their use. 
B. Non-gel-based methods 
In the last five years, there are widespread efforts to develop 
mass-spectrometry based approaches for comparative proteomics. Among 
these, chemical, metabolic or enzymatic stable isotope labeling of 
proteins/peptides in concert with isotope ratio measurement by MS has been 
the most rapidly advancing. A common theme in these methods is that 
chemically identical but mass-differentiated stable isotope tags are introduced 
into the proteins/peptides in two or more sample mixtures. The mixtures are 
combined either before or after proteolysis. Mass spectrometric analysis is 
then performed and differences in abundances of proteins are derived by 
comparing the ion intensities of isotopically labeled peptide pairs. There are 
two main classes in these MS based approaches: in vivo labeling and in vitro 
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labeling. A third MS-based approach intends to provide absolute and relative 
quantitation without the use of isotope-labels.  
B-1: in vivo labeling 
Incorporation of stable isotopes (e.g. 2H, 13C, 15N) into newly synthesized 
proteins using isotope-substituted culture media is a well-established 
technique. Two groups of cells are grown in two separate culture media 
identical in all respects except that one of the media contains the “heavy” 
stable isotopes (e.g. 2H, 13C, 15N). After multiplying the cell population, 
eventually, proteins synthesized in each cell group will be incorporated with 
“heavy” or “light” stable isotopes. Metabolic labeling has a higher fidelity than 
labeling in vitro (incorporating nearly 100% efficiency) and eliminates 
sample-to-sample variability derived from subsequent biochemical 
experiments (119). However, this method only works in cell culture systems 
that allow the incorporation of isotope-substituted media, and may not be 
suitable for animal tissue or body fluids. Furthermore, in the case of 15N 
labeling, both the backbone and side-chain nitrogens are labeled, which 
makes the mass difference between labeled and non-labeled peptides 
unpredictable without a previous knowledge of the peptide sequence (127). 
Several laboratories introduced a modified version of the same overall 
approach, termed SILAC by Mann (128), for stable isotope labeling by 
essential amino acids in cell culture, which makes the mass shift between 
tryptic peptide pairs predictable. For example, Fenselau et. al have reported 
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that growing the parental MCF-7 cell line in 13C6-arginine and 13C6- lysine 
medium resulted in C-terminal labeling of all tryptic peptides and a 6 Dalton 
difference compared to their 12C-counterparts (129). 
B-2: in vitro labeling 
There are far more versions of in vitro labeling than in vivo labeling. The 
former is mostly achieved by chemical derivatization of primary amine or 
C-terminal carboxyl groups in proteolytic peptides. Here I focus on those 
strategies being used most extensively. 
i) Acylation 
One of the initial labeling approaches involved the global coding of tryptic 
peptides through alkylation of their N-terminal amino group and ε-amino 
group on lysine. For example, the technique, also known as global internal 
standard technology (GIST), used 2H3- and 1H3- forms of 
N-acetoxysuccinimide ester for differentially labeling (130). The MALDI-MS 
detection sensitivity with C-terminal lysine-containing peptides, however, is 
much more limited due to the neutralization of the positive charge by acylation 
(120, 131). Furthermore, because peptides coded with 1H3-and 2H3-acetate 
differ by only 3 Dalton there is small overlap between the M+3 isotope peak of 
the 1H3-acetate labeled and the monoisotope peak of the 2H3-actate labeled 
peptide. The overlap needs to be considered to enable accurate isotope ratio 
measurements (120). 
ii) Isotopically coded affinity tags (ICAT) 
 37
This approach involves labeling cysteine-containing peptides from 
different samples with “light” versus “heavy” forms of a reactive chemical, 
which differ by 8 Dalton (132). The ICAT reagent consists of a biotin group 
followed by a linker and terminated with a cysteine-reactive group. The only 
difference between the light and heavy tags is the presence of eight hydrogen 
or deuterium atoms in the linker region. The samples are combined and 
enzymatically digested, and the labeled peptides (cysteine-containing peptides) 
are selectively enriched via bio-avidin affinity chromatography. The specificity 
and advantage of this technique is that it largely reduces the complexity of the 
peptide mixture. Some successful applications in the study of low-abundant 
proteins and membrane bound proteins have been reported (133-135).  
The major limitation of ICAT is that it is only useful to examine 
concentration or structural changes in cysteine-containing peptides, and 
usually protein identifications must be based on a single peptide because 
cysteine is generally present in only 10-20% of the peptides derived from a 
proteome (120, 127). In addition, the peptide isoforms from labeled and 
unlabeled ICAT regents are partially resolved during HPLC separation. A 
second generation of ICAT regents was designed to overcome these problems 
(136-137).  
iii) Multiplexed, isobaric stable isotope tags (iTRAQ) 
The reagents (total of four) were designed to measure up to four samples 
simultaneously. They consist of a charged reporter group that is unique to 
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each of the four reagents (mass range 114 -117 Da), a neutral balance group 
(mass range 31-28 Da) to maintain an overall mass of 145 for each reagent 
and the same peptide reactive group (Figure 8A) (151). The reactive group 
forms an amide linkage to any amino-termini and the ε-amino group of lysine 
side chains. Figure 8B depicts the general labeling procedure. Each individual 
protein sample is digested and labeled with one of the multiplex set separately. 
Then the four peptide mixture are combined and analyzed by LC-MS/MS. Four 
identical peptides from the four different samples will give a single, unresolved 
precursor ion in MS because the overall mass of each labeling reagent is 
identical. But when they are subjected to fragmentation (e.g.CID), the neutral 
balance group is lost from each peptide, leaving four different charged reporter 
groups (m/z range from 114-117 Da) and all other sequence-informative 
fragment ions (e.g. y-, b- ions) which remain as additive isobaric signals. The 
relative concentration of the peptides is thus derived from the relative 
intensities of their corresponding reporter ions. In contrast to ICAT and similar 
mass-different labeling methods, quantitaion of iTRAQ is performed at the 
MS/MS stage rather than in MS.  
There are many advantages of the iTRAQ approach: Up to four samples 
can be compared at the same time; isobaric peptides were generated in MS 
without increasing the complexity of mixture; sensitivity is highly increased in 
MS/MS spectra since all the peptide backbone fragments’ ions are isobaric 









                  Figure 8.  Diagrams of iTRAQ reagents and workflow (151). A, Diagram 
showing the components of the multiplexed isobaric tagging chemistry;  
B, Illustration of the isotopic tagging used to arrive at four isobaric 
combinations with four different reporter group masses 
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that MS/MS spectra must be obtained, which requires more analysis time than 
performing result-dependent analysis only on differentially expressed peptide 
pairs in MS (e.g. ICAT) (151) and good tandem mass spectra can not be 
obtained for all the peptides. 
iv) 18O labeling 
Another simple and robust global labeling strategy is to incorporate two 
atoms of 18O from H218O into new carboxy-termini of peptides during protein 
proteolysis, resulting in a 4 Da mass increase (138-139). All peptides will be 
labeled except the peptide originating from the C-terminus of the protein. A 
variety of serine proteases including trypsin, endoprotease Glu-C, 
endoprotease Lys-C are able to catalyze the exchange of oxygen atoms (140). 
These enzymes form a covalent tetrahedral intermediate with the peptide bond 
of the protein, and the first 18O atom is incorporated through the hydrolysis of 
the peptide bond. After proteolysis is complete, these enzymes continue to 
form reversible covalent intermediates with the carbonyl group of the nascent 
peptide product and then a second 18O atom is introduced by 
pseudohydrolysis (140-141). The repeating binding/hydrolysis cycles result in 
complete equilibration of both oxygens in the C-terminus of the peptides with 
oxygens from solvent water. This mechanism can be seen in figure 9. This 
method has been shown to have at least femtomolar sensitivity (127, 131). 
Chemical back-exchange is reported to happen only under extreme acidic and 
basic conditions (142). The catalytic enzyme must be removed before the 
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sample is exposed to H216O. This is easily done if immobilized trypsin or other 
protease is used. 
18O labeling was originally applied to aid peptide de novo sequencing via 
mass spectrometry (143-144). Fenselau and co-workers developed and 
applied it to quantitative proteomic studies (141), which has also been used by 
other groups (145-149). An improved variation conducts the proteolysis step in 
16O water and a postproteolysis labeling incubation in 18O water (150). Thus 
the proteolytic peptides can be labeled with a limited amount of 18O water and 
both digestion and labeling conditions can be optimized separately.  
18O labeling has a number of advantages over other metabolic and 
chemical labeling methods: it is a natural consequence of protein proteolysis 
involving only one step with none of the exotic reagents or side reactions 
inherent to chemical labeling (145). The concentration of 18O water, 
approaching 55 M, drives the reaction towards completion even for low-level 
proteins; every proteolytic peptide (except those containing the parental 
C-termini) is labeled, which renders global information for protein identification 
and quantitation. As the other labeling strategies, 18O labeling also has its  
downsides including that the 18O exchange will be inhibited by high 
concentrations of urea; the rate of labeling differs with peptide sequence (130). 
 
  






Figure 9.  Mechanism of incorporation of 18O into proteolytic fragments (26)  
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B-3:  Label-free approach 
Even though stable isotope coding continues to be the most powerful 
approach in comparative proteomics, there are disadvantages including the 
cost of isotopic labeling reagents, time-consuming labeling and the 
requirement for pairwise comparisons among samples, which complicates 
multiple and retrospective comparisons(152). Recently, label-free protein 
quantitation techniques have been proposed. Some studies have shown that 
peak intensities of peptide ions in mass spectra correlate well with protein 
abundances in complex samples (152-155). For example, Bondarenko et. al. 
described an approach of adding peak areas of identified peptides from one 
protein to define the total reconstructed peak area (153). The total 
reconstructed peak is further normalized to the peak area of an internal 
standard protein digest present in the mixture at a constant level. They tested 
this method using human plasma and demonstrated linear responses of 
peptide ion peak areas between 10 and 1000 fmol of internal standard with a 
relative standard deviation <11%. In another approach, Liu et. al. found that 
spectral counting, which compares the number of MS/MS spectra assigned to 
each protein accurately reflects relative abundance with a liner correlation over 
a 2 order of magnitude linear dynamic range (155). Later, Old et. al. combined 
these two methods and showed that protein ratios determined by spectral 
counting agreed well with those determined from peak area intensity 
measurements, and both agreed with independent measurements based on 
gel staining intensities (152). But it seems that for real biological samples, such 
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as serum only the abundant proteins can be analyzed using these methods. 
Enrichment of the low abundant proteins is probably required prior to analysis. 
2. Absolute quantitation 
An important application of absolute quantification is as an alternative to 
immunoassays. This is much more difficult than relative quantitation. It is 
normally achieved by spiking known amounts of a synthetic, isotopically coded 
proteolytic peptide as an internal standard (157-161). Thus prior identification 
of the studied peptide/protein and estimation of its absolute amount are often 
needed. Especially, when analyzing a complex mixture, a large investigation is 
required for choosing more than one standard to “mimic” the proteins to be 
analyzed (162). 
Part E 
Hypothesis and objectives 
The development of drug resistance presents a major problem in the 
chemotherapy treatment of cancer patients. Understanding the mechanisms of 
drug resistance is a key step to improve clinical treatment. It is now believed 
that any mutation that disables apoptosis can produce drug resistance. 
Mitochondria play a central role in the apoptosis process. Many proteins 
associated with mitochondria are involved in promoting or evading apoptosis.  
We hypothesize that an investigation of the mitochondrial proteome of drug 
susceptible and drug resistant breast cancer cells should obtain insight into the 
involvement of the mitochondria in the mechanism of acquired drug resistance. 
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The present research aims to study changes in mitochondrial proteins 
associated with drug resistance in human cancer cells. Our specific objectives 
include: 
1) Develop a reproducible method to extract soluble mitochondrial proteins 
form MCF-7 cancer cell mitochondria. 
2) Identify mitochondrial proteins using shotgun analysis consisting of a 
two-dimensional peptide separation based on solution isoeletric focusing 
and reversed-phase HPLC-MS. This methodology can be compared with a 
gel-based strategy previously executed in our laboratory. 
3) Integrate forward and reverse 18O labeling with the two-dimensional 
separation method to identify proteins with altered abundances between a 
drug-susceptible and a mitoxantrane-resistant MCF-7 cancer cell line. 
4) Consider mechanisms of drug resistance based on the functions of those 
altered proteins. 
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Chapter 2:  Experimental 
Materials: 
The drug susceptible and mitoxantrone resistant MCF-7 cell lines were 
provided by Dr. Ken Cowan (Eppley Institute, University of Nebraska Medical 
Center, Omaha, NE). Cell culture flasks were obtained from Corning (Corning, 
NY). MEM was from ATCC (Manassas, VA). Distilled water came from Milli-Q 
water (Billerica, MA). Fetal bovine serum was obtained from Atlanta Biologicals 
(Lawrenceville, GA). Ultracentrifuge tubes were from Beckman Coulter 
(Fullerton, CA). Percoll and IPG buffer (pH 3-10) were purchased from 
Amersham Biosciences (GE Healthcare, Piscataway, New Jersey). Formic 
acid (88%), o-phosphoric acid (85% HPLC) and ammonium bicarbonate were 
obtained from Fisher Scientific (Hampton, NH). Micro Bio-Spin 6 
chromatography columns and protein assay dye reagent concentrate were 
obtained from Bio-Rad (Hercules, CA). PepCleanTM C-18 spin columns and 
bovine serum albumin (2mg/ml) were purchased from Pierce (Rockford, IL). 
Modified porcine trypsin (sequence grade) was purchased from Promega 
(Madison, WI). Ultrafiltration membrane (500 Da molecular weight cut off) 
came from Millipore (Billerica, MA). Multi-compartment eletrolyzer (MCE) kit 
was from Proteome Systems (Woburn, MA). Isotopically enriched H218O 
(>95% 18O) was from Isotech, Inc. (Miamisburg, OH). Poroszyme bulk 
immobilized trypsin was purchased from Applied Biosystems (Foster City, CA). 
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Centrifugal devices (0.45 μ m membrane) were obtained from Pall 
Corporation (East Hills, NY). Sucrose (>99%), penicillin streptomycin solution, 
25% trypsin-EDTA solution, 0.4% trypan blue solution, HEPES (minimum 
99.5%), D-manitol (A.C.S. reagent), sodium hydroxide (A.C.S.), Lysine-L, 
Argine-L (98% TLC), TFA (99%), ACN (HPLC), α-cyano-4-hydroxycinnamic 
acid, Trizma base (minimum 99.9%), PBS (pH 7.4), urea, thiourea, DTT (99%), 
CHAPS, EGTA (minimum 97%), chicken egg white were obtained from Sigma 




The tissue grinder (7ml) was obtained from Kimble Kontes, Fisher 
Scientific (Hampton, NH). The SpeedVac was from Thermo-Savant (Holbrook, 
NY). The Optima LE-80K preparative ultracentrifuge and DU 530 UV-Vis 
spectrometer were from Beckman Coulter (Brea, CA). The sonicator cell 
disruptor (Model W 185 F) was from Heat Systems-Ultrasonics Inc. (Plainview, 
NY). The separation device and electrophoresis tank for solution Isoelectric 
focusing were from Amika Corp. (Columbia, MD). Power supply (power PAC 
3000) for IEF was from Bio-Rad (Hercules, CA). The LCQ-TOF mass 
spectrometer was from ThermoFinnigan (San Jose, CA) LCQ Deca XP 
ion-trap mass spectrometer equipped with a nano-LC electrospray ionization 
source. The ESI-TOF mass spectrometer was from Applied Biosystems 
(Foster City, CA) Qstar Pulsar i with a nanospray ion source from Protana 
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(Odense, Denmark), and the AXIMA-CFR MALDI-TOF mass spectrometer 
was from Kratos, Shimadzu Corporation (Chestnut Ridge, NY). The HPLC with 
UV detector was from Shimadzu SCL-10 AVP instrument (Columbia, CA) with 
a Phenomenex 250mm × 4.6mm, 5µm, C18 column (Torrance, CA). 
Nano-LC-MS/MS was performed on ESI-TOF connected on-line with the nano 
HPLC system, which was consist of Ultimate HPLC, famous autosampler and 
Switchos II all from LC Packing/Dionex (Sunnyvale, CA). The HPLC columns 
used in nano-LC were also from LC packing. The SilicaTip needle was from 
New Objectives (Woburn, WA). BioAnalyst software was from Applied 
Biosystems. MASCOT in-house search engine was purchased from Matrix 
Science (London, UK). 
Methods 
 
Cell culture and harvest 
MCF-7 cell lines were cultured in house. The cells were grown on 150 cm2 
flasks in MEM solution containing 10% fetal bovine serum and 1% penicillin 
streptomycin solution at 37°C and 5% CO2. The cells were harvested at 95% 
confluence (20 flasks per harvest). After removal of the growth medium, cells 
from each flask were washed twice with 25 ml PBS. Then 3ml trypsin-EDTA 
solution was added and incubated at 37℃ to dislodge cells from the flask. After 
3 minutes 13 ml MEM was added to stop tryptic activity. The resulting mixture 
was transferred to pre-weighed centrifugation tubes and centrifuged at 500g 
for 5 minutes. Cell pellet was obtained and then washed twice with PBS.  
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Isolation of mitochondria 
All work in this part was done on ice unless specified otherwise. The 
method of isolating crude mitochondria in this study is modified from the 
Mitochondria Isolation Kit (Sigma) as follows. The cell pellet was suspended 
with 10 volumes of extraction buffer containing 10mM HEPES, pH 7.5, 70mM 
sucrose, 200mM mannitol and 1mM EGTA. The suspension was homogenized 
using a 7 ml Tenbroeck tissue grinder. This cell lysate was stained with 0.4% 
trypan blue solution to monitor the degree of lysis. Upon 75% lysis the 
homogenate was then centrifuged at 600g for 5 minutes. The supernatant 
liquid was transferred to another centrifuge tube. The pellet was re-suspended 
in 5 volume of extraction buffer and homogenization was repeated. Another 
supernatant was obtained after spinning the homogenate at 600g for 5 minutes. 
The two supernatants were combined and centrifuged at 10000g for 20 
minutes to pellet the crude mitochondria fraction.  
The crude mitochondrial pellet was re-suspended in extraction buffer 
(1mg/ml). One milliliter aliquot of the suspension was loaded in centrifuge tube 
containing 20ml of 30% percoll in extraction buffer (163). The mixture was 
spun down at 95000g for 30 minutes in a preparative ultra-centrifuge. 
Mitochondria were collected from the lower fraction and washed twice by being 
diluted into a ten-fold volume of extraction buffer and centrifuged at 10000g for 
20 minutes. The final resulting pellet was the purified mitochondrial fraction. 
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Extraction of mitochondrial proteins 
All work in this part was also done on ice unless specified otherwise. The 
purified mitochondria pellet was re-suspended in 10 mM HEPES buffer (pH 7.4) 
in a ratio of 5 ml solution every 1 gram of mitochondria pellet (163). The 
suspension was vortexed vigorously for 15 seconds every 5 minutes, for a total 
25 minutes. An equal volume of 1.4 M sucrose was then added to the sample 
with further incubation for 20 minutes. The resulting mixture was then 
subjected to treatment for 15 seconds with Sonicator cell disruptor. After one 
minute rest, another 15-second sonication was repeated. The sonicated 
suspension was centrifuged at 15000g for 15 minutes. The obtained pellet 
containing unbroken mitochondria and mitoplasts was discarded. The 
supernatant was diluted with an equal quantity of 100 mM Tris buffer (pH 7.5), 
then centrifuged at 10500g for 50 minutes. The resulting pellet contained 
mitochondrial insoluble protein and the supernatant constituted the soluble 
fraction. Both fractions were stored at -80℃. 
 
Protein assay 
The protein assay for the mitochondrial soluble fraction was based on the 
Bradford method (164). A series of bovine serum albumin dilutions: 0, 1.5, 2.5, 
5, 7.5, 10μg/ml was used to generate the standard curve. The unknown 
sample (from mitochondrial soluble fraction) was diluted properly to obtain a 
concentration which is within the range of standard curve. Two sample 
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dilutions were assayed in triplicate for accuracy and reproducibility. Bio-Rad 
protein assay dye reagent was added to each dilution solution at a volume 
ratio of 1:4 with incubation for at least 5 minutes and no more than 1 hour (165). 
Absorbance was read at 592nm on a DU UV/Vis spectrometer. The protein 
concentration was calculated based on absorbance and dilution factor.  
 
Digestion of Soluble Protein 
The soluble protein fraction was denatured with 6M urea, reduced with 
two 45 minute incubations with 10mM DTT and alkylated by reaction with 
100mM IAA in the dark for 1 hour. The resulting sample was then desalted 
using Bio-Spin 6 size exclusion columns. Each column was centrifuged at 
1000g for 2 minutes to remove the packing buffer. A solution of protein sample 
(no more than 100μl) was loaded directly into the center of the column. The 
column was then centrifuged at 1000g for 4 minutes. The eluate contained the 
desalted protein in 10mM Tris buffer (pH 7.4). A protein assay was performed 
again to measure the recovery of sample. Protein was then digested by 
modified porcine trypsin (1µg trypsin per 50µg protein) at 37°C for 16 hours.  
 
Proteolytic 18O Labeling of mitochondrial soluble proteins 
Immobilized trypsin was washed three times with a five-fold volume of 
distilled water and centrifuged at 1000g for 1 minute each time. Supernatants 
were discarded. To each digested peptide pool a volume of the clean 
immobilized trypsin was added equal to 20% of the sample volume. The 
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mixture was then dried completely by SpeedVac. The pool was redissolved in 
20 % acetonitrile and 80% H218O. The unlabeled peptide counterpart was 
redissolved in 20% acetonitrile and 80% H216O. The solution was rotated at 
37°C for approximately 5 hours on a bench-top rotator. The resulting peptide 
pool was then filtered with a centrifugal filtering device (0.45μm membrane) to 
remove immobilized trypsin. The labeled and unlabeled peptide filtrates were 
combined with a 1:1 ratio. The mixture was then dried by SpeedVac and stored 
at -80℃ to await subsequent separation. 
 
Proteolytic 18O Labeling of lysozyme from chicken egg white 
About 200 µg lysozyme from chicken egg white was dissolved and 
denatured in 200 µl 50 mM Tris (pH 8) and 4 M urea. Then the sample was 
reduced, alkylated and digested as previously mentioned. The digested 
lysozyme solution was divided equally into two pools. Twenty µl immobilized 
trypsin was added to each pool, which were then dried completely in a Speed 
Vac. One pool was redissolved in 80% H218O and 20 % acetonitrile. The other 
pool was redissolved in 80% H216O and 20% acetonitrile. Two pools were 
incubated at 37°C for five hours and then centrifuged at 1,000 g for 2 minutes. 





Forward and Reversed 18O labeling 
In the forward 18O labeling experiment, peptides from drug susceptible cell 
line were labeled with 18O water. In contrast, peptides from drug resistant cell 
line were labeled with 18O water in the reversed 18O labeling experiment. 
 
Solution Isoelectric Focusing (sIEF) Separation 
Six Teflon dialysis chambers including four separation chambers and two 
terminal electrode chambers (500µl volume each) were connected in tandem. 
Five 12mm diameter immobiline gel membranes having different pH values 3, 
5, 6.5, 8 and 11 from an MCE kit were assembled between these chambers 
(Figure 12). Two ultrafiltration membranes (500Da cut-off) were used for 
ending the two terminal electrode chambers. O-rings were used between the 
chambers to assist in sealing the chamber compartments. A sample of the 
dried peptide mixture (0.5~1mg) was redissolved in the Chamber Buffer from 
MCE kit and loaded into the middle two chambers. The two terminal chambers 
were filled with Electrode Buffer from MCE kit while the other chambers were 
all filled with Chamber Buffer. The assembled chambers were put into the 
elctrophoresis tank, which was divided into two parts: cathode and anode 
compartments. Seven mM phosphoric acid was used to fill the anode 
compartment while 20mM lysine and 20mM arginine solution was used for the 
cathode compartment. A Bio-Rad power supply was used to drive isoelectric 
focusing. The running program was: 100V for 10 min, 200V for 20 min, 500 V 
for 40 min and 1000 V for about 100 min, till the current decreased to around 
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0.3~0.6 mA. After focusing, fractionated samples from different chambers were 
collected separately, the surface of the gel membranes and the inside wall of 
the separation chambers were rinsed with 250µl Chamber Buffer and these 
rinses were combined with the appropriate sample. Each solution was dried by 
SpeedVac and stored at -80℃ to await chromatography. 
 
Reversed-Phase HPLC (RPHPLC) analysis with UV Detector 
RP-HPLC was performed with a 250 mm×4.6 mm C18 Column assembled 
with a Shimadzu SCL-10 AVP instrument. The injection volume was 0.5 ml and 
the flow rate was 1ml/min. Buffer A was 0.1% TFA in water and buffer B was 
0.1% TFA in acetonitrile. Each tryptic peptide fraction from the solution IEF 
was loaded into and eluted from the column with an 80 min gradient as follows: 
10% B for 5 min, 10%-60% B for 55 min, 60%-90% B for 10 min, 90% B for 5 




Each dried peptide sample from solution IEF fractionation was purified 
and concentrated using PepClean C-18 spin columns according to the 
manufacturer’s instructions. Each column was activated with 50% ACN and 
then equilibrated with 0.5% TFA in 5% ACN solution. Each peptide sample was 
redissolved in 10% ACN with 1% TFA and loaded onto the column. The 
column was washed with 0.5% TFA in 5% ACN four times to remove high 
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levels of contaminants (i.e., urea, thiourea). The peptide mixture was finally 
eluted with 70% ACN. The eluate was dried by SpeedVac and stored at -80℃ 
before further analysis. 
 
MALDI-TOF Mass Spectrometry  
One µl sample solution was spotted on the MALDI plate and allowed to dry. 
One µl of 25 mM α- cyano-4-hydroxycinnamic acid dissolved in 70% 
acetonitrile in 0.1% TFA was spotted on top of the dried sample. The sample 
was then analyzed on the Kratos AXIMA-CFR MALDI-TOF mass spectrometer 
in reflectron mode. 
 
NanoLC-QqTOF mass spectrometry and protein identification 
The dried peptides recovered from solution IEF were redissolved in 0.1% 
formic acid and separated through LC packing HPLC system. Aliquot (2.2 µl) of 
the peptide mixture was first desalted through a C18 300μm ID × 5 mm 
precolumn for 10 minutes and then introduced to a C18 PepMap 75 µm ID × 
15 cm separation column. Peptide elution was accomplished with 3%-60% B 
for 60 min, 60%-97% B for 10 min, 97% B for 10 min. The effluent at a flow rate 
of 200μl/min was introduced into the ESI-TOF mass spectrometer via an 
uncoated 10μm ID SilicaTip needle hold at 2400V.  The mass spectrometer 
automatically scanned the m/z range 300-1500 Da at 1second/scan. 
Data-dependent control was used to automatically perform MS/MS on the 
most three intensive doubly or triply charged peptides detected in each MS 
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scan. Previously selected precursor ions were excluded for 30 seconds. 
BioAnalyst software submitted the resulting MS/MS spectra to the SwissProt 
human database through the MASCOT in-house search engine (Matrix 
Science, London, UK) to identify peptides and thus their original proteins. 
Criteria used for the searches allow for carbamidomethylation of cysteine and 
oxidation of methionine as variable modifications, one missed cleavage of 
trypsin, and fragment mass tolerance at ±0.8Da. Peptides matched with 
more than 95% confidence are considered to be identified. A scheme for 
peptide and thus protein identification using tandem mass spectra is shown in 
figure 10. 
 
µLC-ion trap mass spectrometry and protein identification 
The desalted peptides were redissolved in 0.1% formic acid. A 10 µl 
sample solution was then injected to the Surveyor HPLC system. The 
reversed-phase separation column was a 75µm ID×10cm fused capillary 
packed with 300Å BioBasic C18 particles, which was connected to a 
nanoelectrospray tip. The peptides were eluted with the same gradient used in 
PR-HPLC-UV described above, at a flow rate ~275 nl/min. The spray voltage 
was 2.0 kV. Acquisition of each full mass spectrum was followed by acquisition 
of MS/MS spectra of the three most intense peaks. Peptide and protein 
identifications were made the same way as mentioned above. 
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Quantitation of the relative abundance of proteins 
The abundance ratios of proteins in drug susceptible and the 
mitoxantrone resistant MCF-7 cells was calculated based on peak area ratios 
in mass spectra of labeled and unlabeled digested peptide pairs in the mixed 
sample. First, an extracted ion chromatogram (XIC) was extracted by summing 
ions in the m/z range of interest using the Extract Ion function on the Analyst 
QS software. XIC gave the pair sets of isotopic clusters with ions 4 Da apart (2 
Da for doubly charged peptides or 1.3 Da for triply charged peptides). Second, 
the observed peak areas for the monoisotope ions for the peptides without 18O 
labeling (I0), the area of peaks with 2 Da higher (I2), and the areas of peaks 
with 4 Da higher (I4) were recorded from the spectrum. Third, the sequence of 
this identified peptide (from earlier identification) was used to calculate the 
theoretical isotope envelope distribution using MS-Isotope program (166). M0 
represents the theoretical peak area for the monoisotope peak for the 
unlabeled peptide, M2 was the peak area for the peaks with masses 2 Da 
higher and M4 was the area of the peak with 4 Da higher. Figure 11 shows an 
extracted ion chromatogram of peptide MEEFKDQLPADECNK 
(+carbamidomethylation, m/z 618.6) from the mixture of 18O labeled and 16O 
labeled peptides, the partial mass spectrum of the pair of doubly charged 
peptides with I0, I2, I4 assignments, and the theoretical isotope clusters of the 
unlabeled peptide (166). The natural isotope distribution pattern for the 18O 
labeled peptide was assumed to be the same. Finally, those experimental data 
 58
and theoretical parameters were inserted into the equation (141) below to 







































=    (Equation 1) 
Incomplete 18O labeling (single incorporation of 18O at the C-terminal of a 
peptide) was considered in this equation in order to obtain a more accurate 
ratio. Ratios from several peptide pairs from the same protein were averaged, 
as well as the ratios for the same protein from three cell harvests to provide 












































Figure 10. Protein identification using tandem MS. A: Total ion chromatogram 
representing summed MS and MS/MS spectra. B: Criteria were chosen for the 
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Figure 11. Relative quantitative analysis of digests of mitochondrial proteins 
prepared in H216O and H218O and combined. A: An extracted chromatogram 
reconstructed by summing ions of m/z 618.6 (MEEFKDQLPADECNK with 
carbamidomethylation, +57 Da) assigned to the triply charged peptide. B: 
Partial mass spectrum of the peak eluting from 31.09 to 31.38 min with I0, I2, I4 




Chapter 3:  Results and Discussion  
 
Mitochondrial isolation and protein extraction 
The mitochondrial fraction was isolated from MCF-7 human cancer cells 
through a reproducible optimized method combining homogenization, 
differential centrifugation and percoll gradient purification. Typically, 3~4 g cell 
pellet was obtained from twenty 150 cm2 flasks, from which ~2 g crude 
mitochondrial pellet could be isolated. Following purification using percoll 
gradient (163), the purified pellet usually had about one-fifth of the weight of 
the original organelle. A balance must be found between sample purity and 
recovery.  
The mitochondrion is a membrane-bound organelle. Swelling of 
mitochondria with hypotonic medium (10mM Hepes, pH=7.3), followed by 
shrinking of mitochondria with isotonic medium (1.4M sucrose), resulted in 
rupture of the outer and inner membranes respectively and thus released 
proteins mostly into the soluble fraction. 
 
Peptide fractionation with solution isoelectric focusing as the first 
dimensional separation 
The proteomic analysis of complex mitochondrial proteins requires the 
separation of the original protein mixture or their digested peptides. The former 
separation was done with a 2-D gel strategy by Dr. Strong, another member in 
our research group (174). As an alternative approach, the latter one, also 
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called shotgun proteomics, is applied in this project. The most common 
strategy of the shotgun approach uses strong cation exchange (SCX) 
chromatography in the first dimension and reversed-phase HPLC as the 
second dimensional separation. But redundancy and relatively small range of 
pI value in peptide identification between fractions were also reported (167). 
Another valuable tool is the separation of proteins/peptides according to their 
pI. In this research, we applied solution isoelectric focusing (sIEF) using a 
small volume device (Amika) as the first dimensional separation to fractionate 
peptide mixture.  
An experimental setup for sIEF is reported in figure 12, which consists of a 
series of Teflon chambers separated by thin porous acrylamide gel 
membranes containing immobilines at specific pH values. In this study, a setup 
made of six chambers was divided by five membranes with pH values of 3.0, 
5.0, 6.5, 8 and 11. The assembled chambers were placed into an 
electrophoresis tank where the anode chamber was immersed into an anode 
buffer and cathode chamber was inside the cathode solution. It can also help 
heat dissipation during the focusing. The peptide sample was dissolved in 
buffer containing high concentrations of urea and thiourea before loading into 
the chambers, which reduced chances of peptide precipitation during focusing 
run. Immobilized pH gradient buffer (IPG buffer, 0.5% V/V) was also added to 













As studied previously in our lab (115), a faster running program (about 
150 min) was set up for focusing peptide mixtures rather than proteins, which 
may also minimize peptide diffusion. Under an electric field, peptides were 
moved and finally trapped in chambers delimited by membranes which 
encompass their pIs. Eventually the electric current decreased to near 0. The 
resulting pI ranges of the six chamber fractions after focusing were: pH = 
below 3, 3-5, 5-6.5, 6.5-8, 8-11 and above 11 respectively.  
Since the peptide mixture in each chamber should have a different 
composition after focusing, reversed phase liquid chromatography with UV 
detector was used to evaluate this separation. Figure 13A shows distinct HPLC 
profiles for different fractions, indicating the separation is effective. The 
reproducibility of this method was examined by performing the separation 
three times for the samples from three cell harvests (Figure 13B). Those 
profiles are similar and most of the peaks appeared in all of the three runs.  
 
Peptide separation with reversed-phase LC/MS/MS as the second 
dimensional separation 
Each chamber fraction was then separated with HPLC coupled on-line for 
MS and tandem MS analysis. Figure 14 shows the “base peak” chromatogram 
of mitochondrial peptides from each fraction of sIEF. The three most intensive 
peptides from the full MS scan were selected automatically for tandem MS 
analysis. Unlike a UV detector, the mass spectrometer is not able to monitor 







Figure 13. UV (214nm) HPLC chromatograms of liquid fractions from solution 
IEF separations.  A.  UV (214nm) HPLC chromatogram of four pI-focused 
liquid fractions (pH 3-5, black trace; 5-6.5, red; 6.5-8, pink; 8-11, green);  B.  
UV (214nm) HPLC chromatogram of a single fraction from three solution IEF 













































Figure 14.  Chromatograms of mitochondrial peptides from sIEF fractions 






pH above 11 
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second/scan. Thus each scan time may only catch portions of eluent at a 
certain time. More important, MS/MS scans are obtained using 
computer-controlled data acquisition and largely rely on ion abundance levels. 
The selection of ions for MS/MS is dependent on the width of the 
chromatographic peaks or the concentration of peptides. Thus there is bias 
toward highly abundant peptides. Repeating the analysis several times may 
analyze new ions, which were lost in previous trials and improve the dynamic 
range of analysis (89, 155). In this work, each sample was analyzed three 
times by LC-MS/MS. 
 
Peptide identification using tandem mass spectrometry 
The MS/MS spectra were submitted to the SwissProt human database 
through a MASCOT in-house search engine with the criteria detailed in the 
Experimental chapter. MASCOT uses probability-based scoring algorithm (72), 
which calculates the probability that the observation of a match between the 
experimental data and the sequence database entry is by chance. Thus lower 
probability is reported as a better match. A widely used threshold for peptide 
identifications is that the probability of a random match is less than 0.05. 
Figure 15 shows examples of MS and MS/MS spectra of a doubly charged 
peptide from chamber 2. The peptide was identified as ILGADTSVDLEETGR 
from its tandem MS spectrum through MASCOT.  
Values of pI for all identified peptides were determined by pI tool in 
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Figure 15. The MS and MS/MS scans of the ion with m/z 788.8.  (A) The MS 
scan of ions eluted at 24.56 min in fraction 2. (B) MS/MS scan from the third 
most abundant ion with m/z 788.8. Peptide ILGADTSVDLEETGR from ATP 




with their calculated pIs and masses is shown in table 1.  
The correlation between peptide pI and chamber pH defined by boundary 
immobiline membranes is presented in figure 16. Each bar shows the pI range 
of identified peptides in each fraction. Fifty percent of the peptides are in the 
box. The line extensions run about between 5% and 95%. The outliers 
represent the peptides having pI values beyond the 5% and 95%. It can be 
seen that the pI ranges from fractions 2 and 5 are located within the pH ranges. 
Peptides in fraction 1 are more basic, while pI values of peptides from 
chambers 3, 4 and 6 are lower than the defined pH ranges. Several reasons 
may contribute to the results. The two terminal fractions come from the 
cathode and anode chambers, which are connected to the amphoteric cathode 
and anode buffers. This might interfere with the focusing of peptides there. The 
intrinsic properties of peptides may play a role in the peptide separation and 
distribution. For example, the actual peptide pIs may be shifted from the 
calculated ones due to their interaction or the property of buffer solution.  
The whole pI range is from ~3-10. There are few tryptic digest peptide 
having pI smaller than 3 or bigger than 11, because trypsin cuts proteins at 
C-termini of arginine and lysine, which have pKa of 9.74 and 10.76 
respectively. This peptide range is similar to the reported result (80), which 
used strong cation exchange chromatography coupled with LC-MS to study 
phosphorylase B. Peptides eluted off SCX by increasing pI. Their pI range can 
be seen in figure 17. In addition, it is interesting to observe that there are fewer 
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Peptide sequence pI MW 
VPLPSLSPTMQAGTIAR 9.72 1739.1  
LLGGVTIAQGGVLPNIQAVLLPK  9.72 2271.8  
DVPIGAIICITVGKPEDIEAFK  4.32 2328.8  
DFLAGGVAAAISK 5.84 1219.4  
TITLEVEPSDTIENVK 4 1788.0  
ESTLHLVLR  6.85 1067.3  
IQTQPGYANTLR  8.75 1361.5  
NAGVEGSLIVEK  4.53 1215.4  
VGGTSDVEVNEK  4.14 1233.3  
TLNDELEIIEGMK  4 1504.7  
CIPALDSLTPANEDQK  4.03 1714.9  
IQEIIEQLDVTTSEYEKEK  4.14 2295.5  
IMQSSSEVGYDAMAGDFVNMVEK  3.92 2508.8  
LVQDVANNTNEEAGDGTTTATVLAR  3.92 2560.7  
TVIIEQSWGSPK 5.66 1344.5  
ISSIQSIVPALEIANAHR 6.75 1919.2  
KPLVIIAEDVDGEALSTLVLNR 4.32 2365.8  
DPGMGAMGGMGGGMGGGMF  3.8 1675.0  
VGEVIVTK  5.97 844.0  
LSDGVAVLK  5.84 901.1  
GVMLAVDAVIAELK  4.37 1428.8  
AAVEEGIVLGGGCALLR  4.53 1627.9  
ALMLQGVDLLADAVAVTMGPK  4.21 2113.6  
QSKPVTTPEEIAQVATISANGDK  4.68 2384.6  
TALLDAAGVASLLTTAEVVVTEIPK  4.14 2482.9  
GVMLAVDAVIAELKK  6.07 1556.9  
VGLQVVAVK  8.72 912.1  
GYISPYFINTSK  8.5 1389.6  
KISSIQSIVPALEIANAHR  8.75 2047.4  
TALLDAAGVASLLTTAEVVVTEIPKEEK  4.25 2869.3  
DDAMLLK  4.21 805.0  
GIIDPTK  5.84 742.9  
EIGNIISDAMK  4.37 1190.4  
IQEIIEQLDVTTSEYEK  3.91 2038.2  
TLNDELEIIEGMKFDR  4.18 1923.2  
ISSIQSIVPALEIANAHR  6.75 1919.2  
IQEAGTEVVK  4.53 1073.2  
TIIPLISQCTPK 7.89 1313.6  
VDFPQDQLTALTGR  4.21 1560.7  
MISDAIPELK  4.37 1116.3  
GCDVVVIPAGVPR  5.83 1281.5  
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Peptide sequence pI MW 
GCDVVVIPAGVPRKPGMTR  9.5 1952.4  
LTLYDIAHTPGVAADLSHIETK  5.21 2365.7  
AVLGASGGIGQPLSLLLK  8.8 1694.1  
GYLGPEQLPDCLKGCDVVVIPAGVPR  4.56 2696.2  
ANTFVAELK  6.05 992.1  
FDGILGMAYPR  5.84 1239.5  
DPDAQPGGELMLGGTDSK 3.84 1787.9  
VVDALGNAIDGK  4.21 1171.3  
TGTAEMSSILEER  4.25 1423.6  
ILGADTSVDLEETGR  3.92 1575.7  
TGAIVDVPVGEELLGR  4.14 1624.9  
NVQAEEMVEFSSGLK 4.25 1667.9  
YEELQSLAGK  4.53 1137.3  
AEAESMYQIK  4.5 1169.3  
SLDMDSIIAEVK  4.03 1320.5  
ASLEAAIADAEQR  4.14 1344.4  
LEGLTDEINFLR  4.14 1419.6  
LSELEAALQR 4.53 1129.3  
LVSESSDVLPK  4.37 1173.3  
LESGMQNMSIHTK  6.75 1475.7  
TEMENEFVLIK  4.25 1352.6  
QLYEEEIR  4.25 1079.2  
LEAELGNMQGLVEDFK  4 1793.0  
YSTDVSVDEVK  4.03 1241.3  
IIAEGANGPTTPEADK  4.14 1583.7  
GFIGPGIDVPAPDMSTGER  4.03 1916.1  
IIAEGANGPTTPEADKIFLER  4.41 2242.5  
HGGTIPIVPTAEFQDR  5.32 1737.9  
AKPYEGSILEADCDILIPAASEK  4.18 2433.8  
NIMVIPDLYLNAGGVTVSYFEWLK  4.37 2743.2  
NILGGTVFREPIICK  8.22 1660.0  
DQTDDQVTIDSALATQK  3.77 1848.9  
VCVETVESGAMTK  4.53 1353.6  
TIEAEAAHGTVTR  5.37 1355.5  
LNEHFLNTTDFLDTIK  4.54 1921.1  
VAKPVVEMDGDEMTR  4.32 1676.9  
YFDLGLPNR  5.84 1094.2  
NILGGTVFR  9.75 976.1  
DIFQEIFDK  4.03 1154.3  
LEVAPISDIIAIK  4.37 1381.7  
GTSFDAAATSGGSASSEK  4.37 1630.6  
ASSTSPVEISEWLDQK  4.14 1776.9  
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AAVDAGFVPNDMQVGQTGK  4.21 1905.1  
VFSVRGTSFDAAATSGGSASSEK 6.04 2219.4  
VVPEMTEILK  4.53 1158.4  
GLLPEELTPLILATQK  4.53 1736.1  
LLYDLADQLHAAVGASR  5.21 1813.0  
TIVAINKDPEAPIFQVADYGIVADLFK  4.23 2948.4  
IVAPELYIAVGISGAIQHLAGMK  6.75 2351.8  
LGGEVSCLVAGTK  5.99 1233.5  
GLVYETSVLDPDEGIR  3.92 1762.9  
EGSGIGAIDSNLDWSHNFTNMLGYTDHQFTELTR  4.42 3828.1  
TVVGQITVDMMYGGMR  5.5 1758.1  
HLPNDPMFK  6.74 1098.3  
DILADLIPK  4.21 997.2  
YWELIYEDSMDLIAK  3.92 1889.2  
ALLTAAARLLGTK  11 1298.6  
IDYGEYMDK  4.03 1133.2  
SGDSEVYQLGDVSQK  4.03 1611.7  
NPVTIFSLATNEMWR  6 1779.0  
RQATTIIADNIIFLSDQTK  5.96 2148.4  
IDVSIEAASGGK  4.37 1146.3  
NLGLEELGIELDPR  4 1567.8  
SEEQLKEEGIEYK  4.32 1581.7  
NETLGGTCLNVGCIPSK  5.99 1706.0  
IPNIYAIGDVVAGPMLAHK  6.74 1979.4  
VWDDGIIDPADTR  3.77 1472.6  
VLDSITTEILK 5.97 1213.5 
QGTIFLAGPPLVK 8.75 1340.6  
FEEEGNPYYSSAR  4.25 1548.6  
KLEAAEDIAYQLSR 4.68 1606.8  
ILFRPVASQLPR 12 1396.7 
FDAGELITQR 4.37 1149.3 
IFTSIGEDYDER 3.92 1444.5 
LDVTIEPSEEPLFPADELYGIVGANLK  3.77 2930.3  
IEYDTFGELK  4.14 1214.3  
AAAEVNQDYGLDPK  4.03 1490.6  
AIEMLGGELGSK  4.53 1204.4  
IYELAAGGTAVGTGLNTR  6 1764.0  
THTQDAVPLTLGQEFSGYVQQVK  5.29 2546.8  
ETAIELGYLTAEQFDEWVKPK  4.25 2467.8  
DDIENMVK  4.03 963.1  
TTPSVVAFTADGER  4.37 1450.6  
EQQIVIQSSGGLSK  6.1 1473.7  
 75
Peptide sequence pI MW 
VINEPTAAALAYGLDK  4.37 1645.9  
MEEFKDQLPADECNK  4.18 1797.0  
VEAVNMAEGIIHDTETK  4.4 1857.1  
STNGDTFLGGEDFDQALLR  3.84 2056.2  
EQQIVIQSSGGLSKDDIENMVK  4.32 2418.7  
CELSSVQTDINLPYLTMDSSGPK 4.03 2498.8  
QAVTNPNNTFYATK 8.59 1568.7  
ASNGDAWVEAHGK  5.32 1341.4  
SDIGEVILVGGMTR  4.37 1446.7  
NAVITVPAYFNDSQR  5.84 1694.9  
SQVFSTAADGQTQVEIK  4.37 1809.0  
ERVEAVNMAEGIIHDTETK  4.57 2142.4  
EMAGDNKLLGQFTLIGIPPAPR  6.17 2338.8  
MKETAENYLGHTAK  6.51 1333.4  
LYSPSQIGAFVLMK  8.59 1553.9  
DAGQISGLNVLR  5.84 1242.4  
RDYASEAIK  6.07 1052.2  
AANDAGYFNDEMAPIEVK  3.92 1955.1  
TNVNGGAIALGHPLGGSGSR 9.44 1835.0  
QTMQVDEHARPQTTLEQLQK  5.45 2381.7  
DGTVTAGNASGVADGAGAVIIASEDAVK  3.84 2516.7  
VSPETVDSVIMGNVLQSSSDAIYLAR  4.03 2752.1  
INFDDNAEFR  4.03 1240.3  
FFVADTANEALEAAK  4.14 1596.8  
DIFAMDDKSENEPIENEAAK  3.95 2266.4  
SCNGPVLVGSPQGGVDIEEVAASNPELIFK  4 3027.4  
LVAGEMGQNEPDQGGQR  4.14 1785.9  
LGDPAEYAHLVQAIIENPFLNGEVIR  4.4 2879.3  
VDVAVNCAGIAVASK  5.8 1416.7  
LVGQGASAVLLDLPNSGGEAQAK  4.37 2195.5  
DVQTALALAK  5.84 1029.2  
IQEENVIPR  4.53 1097.2  
GDVENIEVVQK  4.14 1229.4  
VIEEQLEPAVEK  4.09 1383.6  
MEEANIQPNR  4.53 1201.3  
VEDALNLK  4.37 901.0  
IPENIYR  6 904.0  
DLPVTEAVFSALVTGHAR  5.32 1883.1  
GDEELDSLIK  3.92 1118.2  
TVQSLEIDLDSMR  4.03 1506.7  
GGMGSGGLATGIAGGLAGMGGIQNEK  6 2261.6  
LLEDGEDFNLGDALDSSNSMQTIQK  3.66 2740.9  
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LEAEIATYR 4.53 1065.2  
TITLEVEPSDTIENVK 4 1788.0  
LQLETEIEALKEELLFMK  4.33 2177.6  
DWSHYFK  6.74 982.1  
VIHDNFGIVEGLMTTVHAITATQK  5.99 2596.0  
IISNASCTTNCLAPLAK 8.06 1720.0  
VPTANVSVVDLTCR 5.8 1473.7  
GGMGSGGLATGIAGGLAGMGGIQNEK  6 2261.6  
TVQGPPTSDDIFER  4.03 1561.7  
VLPMNTGVEAGETACK  4.53 1619.9  
AFYNNVLGEYEEYITK  4.25 1953.1  
ALQDPNVAAFMVEPIQGEAGVVVPDPGYLMGVR  3.92 3441.0  
VGDAIPAVEVFEGEPGNK  4 1828.0  
VGDAIPAVEVFEGEPGNKVNLAELFK  4.25 2743.1  
GVVDSEDIPLNLSR  4.03 1513.7  
APALAAVPGGKPILCPR  9.51 1631.0  
AFLDALQNQAEASSK  4.37 1592.7  
EGIVTATEQEVK  4.25 1303.4  
VTIAQGGVLPNIQAVLLPK  8.72 1931.4  
VETTEDLVAK  4.14 1104.2  
LSVISVEDPPQR  4.37 1339.5  
GIHVEVPPAEAER  4.75 1403.6  
IEVIKPGDLGVDLTSK  4.56 1684.0  
KIEVIKPGDLGVDLTSK  6.12 1812.1  
EIDGGLETLR  4.14 1102.2  
LPAVVTADLR  5.84 1054.3  
IDTIEIITDR  4.03 1188.3  
TLADAEGDVFR  4.03 1193.3  
VNAGDQPGADLGPLITPQAK  4.21 1962.2  
EEDATLSSPAVVMPTMGR  4.14 1891.1  
GLQVVEHACSVTSLMMGETMPSITK  5.4 2650.1  
SSDPDYLAAVDK  3.93 1280.4  
TTLPQDCSNPAPLSSPLNGVHDR  5.18 2419.7  
VVDFIDEGVNIGLEVK  3.92 1746.0  
GWTGQESLSDSDPEMWELLQR 3.83 2464.7  
IMGLDLPDGGHLTHGYMSDVK  5.13 2256.6  
AALEALGSCLNNK  6.04 1303.5  
AHLLADMAHISGLVAAK  6.96 1718.1  
GYSLVSGGTDNHLVLVDLRPK  6.75 2240.5  
EVCDEVKAHLLADMAHISGLVAAK  5.32 2520.9  
VLELVSITANK  5.97 1186.4  
LMCPQEIVDYIADK  4.03 1637.9  
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LMCPQEIVDYIADKK  4.56 1766.1  
GELFWDDGESLEVLER  3.77 1894.0  
APSPLYSVEFSEEPFGVIVHR  4.75 2360.7  
TVGIDDLTGEPLIQR  4.03 1626.8  
YEEIDNAPEER  3.91 1364.4  
KYEEIDNAPEER  4.25 1492.6  
LLDAVDTYIPVPAR  4.21 1542.8  
GEETPVIVGSALCALEGR  4.25 1801.0  
TIGTGLVTNTLAMTEEEK  4.25 1908.2  
NMITGTAPLDGCILVVAANDGPMPQTR  4.21 2756.2  
QIGVEHVVVYVNK  6.75 1483.7  
GITINAAHVEYSTAAR  6.75 1673.9  
DLEKPFLLPVEAVYSVPGR  4.68 2129.5  
ALEAANGELEVK  4.25 1243.4  
FVSSSSSGGYGGGYGGVLTASDGLLAGNEK  4.37 2795.0  
SLLEGQEDHYNNLSASK  4.65 1905.0  
ILGATIENSR  6 1073.2  
AFVDFLSDEIK  4.03 1283.4  
VEEQEPELTSTPNFVVEVIK  3.98 2287.6  
MSGGWELELNGTEAK  4.25 1621.8  
ILTMDGLIEDIK  4.03 1360.6  
NVEAMNFADIER  4.14 1408.6  
TPAFAESVTEGDVR  4.14 1478.6  
GLVVPVIR  9.75 852.1  
AKPAEAPAAAAPK  8.64 1192.4  
TGAAPAKAKPAEAPAAAAPK  9.7 1789.1  
SYELPDGQVITIGNER  4.14 1791.0  
SENGLEFTSSGSANTETTK  4.25 1960.0  
TDEFQLHTNVNDGTEFGGSIYQK  4.31 2600.7  
VNNSSLIGLGYTQTLKPGIK  9.7 2103.5  
LNNDDNVDGLLVQLPLPEHIDER  3.96 2628.9  
EAAGEGPALYEDPPDQK  3.83 1786.9  
PEFLEDPSVLTK  4.14 1374.6  
ALNALCDGLIDELNQALK  4.03 1914.2  
NNTVGLIQLNRPK 11 1466.7  
SLAMEMVLTGDR  4.37 1322.6  
ICPVETLVEEAIQCAEK  9.6 1283.4  
VLVEPDAGAGVAVMK  4.37 1455.7  
NPPVNSLSLEFLTELVISLEK  4.25 2342.7  
DADVQNFVSFISK  4.21 1469.6  
TYEQVLENLESK  4.25 1452.6  
FLGTEPEPDAVGLDSGHIR  4.31 2010.3  
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AIQGGLEWLK  6.05 1114.3  
QVVEEPSPQLPADK  4.14 1536.7  
VECVGDDIAWMR  4.03 1393.6  
VLSGDLGQLPTGIR  5.81 1425.7  
LGTPVLQALGDGDFVK  4.21 1629.9  
SYLTEQVNQDLPK  4.37 1534.7  
QCPIMDPAWEAPEGVPIDAIIFGGR  3.92 2683.1  
DEGWLAEHMLILGITSPAGK  4.65 2138.5  
KDPEPEDEVPDVK  4.02 1496.6  
DPEPEDEVPDVK  3.71 1368.4  
GDVVNQDDLYQALASGK  3.93 1792.9  
QLEVEPEEPEAENK  3.9 1640.7  
VVDNPIYLSDMGAALTGAESHELQDVLEETNIPKR  4.19 3826.3  
VPTAAGAWLLR  9.72 1154.4  
TENPLILIDEVDK  3.92 1498.7  
AKLSSDVLTLLIK  8.64 1400.7  
TPLAVELEVLDGHDPDPGR  4.1 2030.2  
QAEVANQETKEDLPAENGETK  4.14 2301.4  
TPDGTENGDFLALDLGGTNFR  3.84 2210.3  
AQAELVGTADEATR  4.14 1431.5  
SYELPDGQVITIGNER  4.14 1791.0  
YPIEHGIITNWDDMEK  4.31 1961.2  
VAPEEHPVLLTEAPLNPK  4.75 1954.3  
QEYDESGPSIVHR  4.65 1516.6  
SYELPDGQVITIGNER  4.14 1791.0  
LCYVALDFEQEMATAASSSSLEK  4 2493.8  
VTINTAIGHINR  9.73 1308.5  
AFGGQSLK  8.8 806.9  
CCCVADR  5.82 768.9  
ISKLYGDLK  8.5 1036.2  
HVNGQDQIVPGLYACGEAACASVHGANR  5.99 2838.1  
NTVVATGGYGR  8.75 1094.2  
GEGGILINSQGER  4.53 1329.4  
VPPIKPNAGEESVMNLDK  4.68 1938.2  
LRLEVNLQAMK  8.75 1314.6  
GALAK  8.75 458.6  
LEATQLEGVAR  4.53 1186.3  
DMPAAGSLGSSSRNR  9.6 1505.6  
YSTDVSVDEVK  4.03 1241.3  
DDGSWEVIEGYR  3.92 1425.5  
SHSLKDLAMVE  5.48 1229.4  
GDGSCDVR  4.21 807.8  
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DAGEGGLSLAVEGPSK  4.14 1486.6  
CTYRPAMEGPHTVHVAFAGAPITR  8.24 2583.0  
QVAEVNLWGTVRMTK  8.75 1732.0  
LRTVQLNVCSSEEVEK  4.79 1834.1  
LFLTMEINPK  6 1205.5  
TSAPITCELLNK  5.66 1289.5  
ELLGAAGHR  6.85 923.0  
GHALRDTETTLR  6.75 1369.5  
VLINLYCCAAEDAR  4.37 1553.8  
AAAAK  8.8 430.5  
NETEIELGSLLR  4.25 1373.5  
QHMAQMEEMKTR  6.76 1519.8  
QEATESLKCQEELR  4.49 1663.8  
SPGSGCILAHCMGLGK  7.82 1530.8  
GMYQPVAGGMQPPPLQR  8.75 1827.2  
QKTELMK  8.59 877.1  
ADFEEQLWKK  4.68 1293.4  
VLDSGAPIKIPVGPETLGR  6.04 1919.3  
TIAMDGTEGLVR  4.37 1262.4  
IMNVIGEPIDER  4.14 1385.6  
IPSAVGYQPTLATDMGTMQER  4.37 2266.6  
TVLIMELINNVAK  5.66 1457.8  
LVLEVAQHLGESTVR  5.4 1650.9  
IGLFGGAGVGK  8.75 975.2  
SLQDIIAILGMDELSEEDKLTVSR  4.02 2676.0  
IPVGPETLGR  6 1038.2  
VALVYGQMNEPPGAR  5.97 1601.8  
LLKMAVGMR  11 1018.3  
SPLAQRPLR  12 1037.2  
ISSPCLKADSGACGPDSCPYCAR  5.93 2301.6  
GKGGEIQPVSVK  8.59 1198.4  
VLQATVVAVGSGSK  8.72 1315.5  
VLLPEYGGTK  5.97 1076.3  
GGEIQPVSVK  6 1013.2  
FLPLFDR  5.84 907.1  
GAPTTSLISVAVTK  8.75 1344.6  
FQNEEEVFAWNNEVK  4.09 1883.0  
GEVITTYCPANNEPIAR  4.53 1848.1  
VNLLSFTGSTQVGK  8.72 1450.7  
LQQAPNQPK  8.75 1023.2  
FVTVQTISGTGALR  9.75 1449.7  
ISVAGVTSSNVGYLAHAIHQVTK  8.61 2352.7  
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IAAAILNTPDLR  5.84 1267.5  
DDNGKPYVLPSVR  5.96 1459.6  
VNNSSLIGVGYTQTLRPGVK  9.99 2103.4  
WNTDNTLGTEIAIEDQICQGLK  3.92 2462.7  
QEYDESGPSIVHR  4.65 1516.6  
SYELPDGQVITIGNER  4.14 1791.0  
VAPEEHPVLLTEAPLNPK  4.75 1954.3  
AQQATPGGAAPTIFSR  9.79 1572.7  
ISQAEEEDQQLLGHLLLVAK  4.4 2234.5  
APALGGSFAGLEPMGLLWALEPEKPLVR  4.79 2920.5  
TMETLHLEYFEEAMNYLLSHPEVK  4.62 2925.3  
KHPDASVNLSEFSK  6.75 1558.7  
LGEMWNNTAADDKQPYEK  4.32 2110.3  
APEQEQAAPGPAAGGEAPK  4.25 1775.9  
AEPPKAPEQEQAAPGPAAGGEAPK  4.49 2298.5  
AQGPAASAEEPKPVEAPAANSDQTVTVK  4.41 2764.0  
AAEAAAAPAESAAPAAGEEPSKEEGEPK  4.12 2636.8  
ITDLANLSAANHDAAIFPGGFGAAK  5.21 2441.7  
GVEVTVGHEQEEGGKWPYAGTAEAIK  4.64 1554.6  
GGAEVQIFAPDVPQMHVIDHTK  5.21 2389.7  
GFLNSSELSGLPAGPDR  4.37 1716.9  
LGQHVVGMAPLSVGSLDDEPGGEAETK  4.17 2694.0  
LIAINANDPEASK  4.37 1355.5  
ILGILALIDEGETDWK  3.92 1786.1  
NVTGHYISPFHDIPLK  6.92 1838.1  
NDEYENLFNMIVEIPR  4 1996.2  
IEQLSPFPFDLLLK  4.37 1660.0  
YAELLVSQGVVNQPEYEEEISK  3.98 2524.8  
VIPEDGPAAQNPENVK  4.14 1677.8  
GSGDPSSSSSSGNPLVYLDVDANGKPLGR  4.43 2834.0  
LPAARACSK  9.51 916.1  
VGNGFEEGTTQGPLINEK  4.25 1890.0  
ISFTGSTTTGK  8.75 1099.2  
FSHEEIAMATVTALR  5.4 1675.9  
YTPSGQAGAAASESLFVSNHAY  5.24 2228.4  
ADDGRPFPQVIK  6 1342.5  
STELLIR  5.72 831.0  
TVTAMDVVYALK  5.5 1310.6  
DNIQGITKPAIR  8.75 1325.5  
VVQVSAGDSHTAALTDDGR  4.41 1899.0  
ALGSVGPVDLLVNNAAVALLQPFLEVTK  4.37 2849.4  
VNAVNPTVVMTSMGQATWSDPHK  6.71 2470.8  
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NEQDAYAINSYTR  4.37 1544.6  
QAVLGAGLPISTPCTTINK  8.22 1884.2  
ENGTVTAANASTLNDGAAALVLMTADAAK  4.03 2762.0  
FGNEVIPVTVTVK  6 1402.7  
AFQYVETHGEVCPANWTPDSPTIKPSPAASK  5.45 3329.7  
HLSVNDLPVGR  6.74 1206.4  
NGGLGHMNIALLSDLTK  6.74 1754.0  
DYGVLLEGSGLALR  4.37 1462.7  
VLVHPPQDGEDEPTLVQK  4.31 2001.2  
EPVEAAPAAEPVPAST  3.67 1535.7  
GQLTTDQVFPYPSVLNEEQTQFLK  4.14 2783.1  
GFGGITHGPPEK  6.75 1196.3  
LVEIVGMHDLGVGITLGAHQSIGFK  5.99 2592.1  
TPVTDPATGAVK  5.5 1156.3  
ELGAFGLQVPSELGGVGLCNTQYAR  4.53 2579.9  
IGIIDGEYVVNPTR  4.37 1545.8  
TLNDRSSIVMGEPISQSSSNSQ  4.37 2337.5  
SETAPAAPAAAPPAEK  4.53 1478.6  
LLQYSDALEHLLTTGQGVVLER  4.65 2455.8  
VEGSFPVTMLPGDGVGPELMHAVK  4.65 2467.9  
IESEGLLSLTTQLVK  4.53 1630.9  
SETAPAETATPAPVEK  4.25 1598.7  
ATGPPVSELITK  6.05 1212.4  
KATGPPVSELITK  8.59 1340.6  
ATGPPVSELITKAVAASK  8.64 1740.0  
TVAGIIVEPIQSEGGDNHASDDFFR  4.1 2674.9  
REDLLNNAAHAGK  6.75 1408.5  
MLDLYSQISSVPIGYSHPALLK  6.49 2432.9  
VDVEFDYDGPLMK  3.84 1527.7  
GTFCSFDTPDDSIR  3.92 1560.7  
IDIPSFDWPIAPFPR  4.21 1771.1  
NLLLAEVINIIK  6 1352.7  
HELQANCYEEVKDR  4.83 1733.9  
HGYPLIIYDVFPDACK  5.21 1851.2  
TPVGFIGLGNMGNPMAK  8.41 1704.0  
MGAVFMDAPVSGGVGAAR  5.59 1693.0  
KPAEQAEETAPIEATATKEEEGSS  4.12 2503.6  
VNDNKTAAEEALR  4.68 1430.5  
TIAQGNLSNTDVQAAK  5.5 1630.8  
VTSEELHYFVQNHFTSAR  6 2165.4  
AVAFQNPQTHVIENLHAAAYR  6.96 2350.6  
QKAAAAFAQLQGAMEMLGISESEQR  4.79 2666.0  
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NMDAHKVMLDLLQIPYDK  5.3 2144.5  
CVVEPAAGDLDNPPK  4.03 1524.7  
LYQGHLQEESGPPPESMPK  4.75 2124.4  
YLESEEYQER  4.09 1345.4  
NGPLEVAGAAVSAGHGLPAK  6.75 1816.1  
SIAFPSIGSGR  9.47 1091.2  
ASGPPVSELITK  6.05 1198.4  
VAGHPNIVINNAAGNFISPTER  6.72 2291.6  
DPDMVQNTVSELIK  4.03 1588.8 
ILMAAPGMAIPPFIMNTLEK 6 2158.7 
GMTTLLSSLGAQCVIASRK  9.51 1936.3  
VAFTGSTEVGHLIQK  6.72 1586.8  
LAPALATGNTVVMK  8.75 1385.7  
VAEAHENIIHGSGATGK  6 1690.8  
TQHHVEALVEHQNGK  6.19 1726.9  
GPGGSSLLIEALSNSSHK  6.75 1753.9  
ALEMAIEAGAEDVKETEDEEER  3.84 2464.6  
AADLQLEMTQKPHK  6.8 1609.9  
KPGPGEPLVFGK  8.59 1225.5  
LGGNYGPTVLVQQEALKR  8.59 1943.2  
LFDFQGLQHQVAHVATQLEAAR  5.99 2479.8  
VGSFCLSEAGAGSDSFALK  4.37 1846.0  
IGTIYEGASNIQLNTIAK  6 1906.2  
LDSPAGTALSPSGHTK  6.74 1538.7  
IQEPNTFPAILR  6 1398.6  
QIGLLLK  8.75 784.0  
MSLWGLVSK  8.5 1020.3  
LGGDLGTYVINK  5.83 1249.4  
FAAEHTIFASNTSSLQITSIANATTR  6.75 2753.0  
TPMTSQKTFESLVDFSK  5.73 1946.2  
TFESLVDFSK  4.37 1172.3  
TLSTIATSTDAASVVHSTDLVVEAIVENLK  4.31 3085.5  
HVTVIGGGLMGAGIAQVAAATGHTVVLVDQTEDILAK 5.21 3614.2  
DTPGFIVNR  5.84 1018.1  
GNIETNHNLPPSHK  6.92 1557.7  
IGGIGTVPVGR  9.75 1025.2  
VMPNAIVQSVGVSSGK  8.72 1572.8  
TLQYLSQGNVVFK  8.26 1496.7  
TGQAPGYSYTAANK  8.17 1428.5  
ADLIAYLK  5.88 906.1  
ASGPPVSELITK  6.05 1198.4  
SETAPAAPAAPAPAEK  4.53 1478.6  
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RGDIIGVQGNPGK  8.75 1310.5  
QTLSTPGTIILGTIPVPK  8.75 1836.2  
ISALQSAGVVVSMSPAQLGTTIYK  8.59 2421.8  
VSGVMDNNILVLVPDPHAK  5.21 2018.4  
VPFCLQSCVKPLK  8.9 1461.8  
GSTHPQPGVSPPAAPAAPGPK  8.76 1921.1  
VRLAWAALAR  12 1126.4  
IAEEFEVELER  3.98 1663.5  
AEAEAQAEELSFPR  4.09 1547.6  
HGEEVTPEDVLSAAMYPDVFAHFK  4.49 2690.0  
VAVEEVDEEGK  3.91 1203.3  
MQQQLDEYQELLDIK  3.92 1894.1  
TLEGELHDLR  4.65 1182.3  
QELIECVANSDEQLGEMFLEEK  3.77 2554.8  
YLEATGQLPVK  6 1218.4  
TGIEQGSDAGYLCESQK  4.14 1785.9  
TGIEQGSDAGYLCESQKFGELVMTK  4.41 2692.0  
EDLPAENGETKTEESPASDEAGEK  3.89 2533.6  
IQDVGLVPMGGVMSGAVPAAAAQEAVEEDIPIAK  3.83 3334.9  
AALEAVGGTVVLE  4.24 1228.4  
GVVDSEDLPLNISR  4.03 1513.7  
EGLELPEDEEEK  3.77 1416.5  
EDQTEYLEER  3.91 1311.3  
GDVGMAGVAIDTVEDTK  3.84 1677.8  
VADPWGGSYMMECLTNDVYDAALK  3.84 2650.0  
SVTEQGAELSNEER  4.09 1548.6  
DSTLIMQLLR  5.84 1189.4  
EAAGEGPALYEDPPDQK  3.83 1786.9  
SVTNEDVTQEELGGAK  4 1676.8  
EVDVGLAADVGTLER  3.92 1543.7  
YQETFNVIER  4.53 1298.4  
LIAEGPGETVLVAEEEAAR  3.98 1954.2  
GEPAAAAAPEAGASPVEK  4.25 1622.8  
ALYETELADAR  4.14 1251.4  
QASIQHIQNAIDTEK  5.32 1695.9  
YGLIPEEFFQFLYPK  4.53 1891.2  
EISEVFPDQFIHLGGDEVEFK  4.08 2435.7  
VAPTVETSDPYADDPVR  3.84 1832.0  
DAINQGMDEELERDEK  3.95 1892.0  
DIIFAIK  5.84 819.0  
TNHLVTVEGGWPQFGVGAEICAR  5.34 2441.8  
DVQGTDASLDEELDR  3.66 1662.7  
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Peptide sequence pI MW 
TEGDEEAEEEQEENLEASGDYK  3.55 2501.4  
HYLPLSSILDTLDVMAYNK  5.21 2193.5  
GSYNPVTHIYTAQDVK  6.74 1793.0  
TPYTDVNIVTIR  5.5 1391.6  
GEFDPGQDTYQHPPK  4.54 1715.8  
IVYGHLDDPASQEIER  4.31 1842.0  
LEAPDADELPK  3.92 1197.3  
EDIANLADEFK  3.92 1264.4  
DLEDLQILIK  4.03 1199.4  
LPHLPGLEDLGIQATPLELK  4.65 2154.5  
STELLIR  5.72 831.0  
KEEILLIK  6.14 985.2  
HLNFLTSEQALADFAELIK  4.65 2160.5  
GLDTVVALLADVVLQPR  4.21 1779.1  
GKPAVAALGDLTDLPTYEHIQTALSSK  5.38 2797.2  
CPGESSHICDFIR  6 1463.7  
TPLFDQIIDMLR  4.21 1461.7 
PGLVDSNPAPPESQEK  4.14 1664.8  
APSVPAAEPEYPK  4.53 1355.5  
HEWVTTENGIGTVGISNFAQEALGDVVYCSLPEVGTK 4.25 3922.3  
NMITGTSQADCAVLIVAAGVGEFEAGISK  4.14 2853.3  
IITLEEGDIILTGTPK  4.14 1713.0  
IPGIYVLSLEIGK  6 1401.7  
CPGESSHICDFIR  5.32 1463.5  
VVNSETPVVVDFHAQWCGPCK  5.32 2315.7  
DEDQLEAFLK  3.92 1207.3  
SPALLLSQLLPYMENR  5.72 1845.2  
EPGTVALVSK  6.1 1000.2  
DLLEVADVLEK  3.92 1243.4  
FDPYEHEALFHTPVEGK 4.8 2016.2  
VVPLVQMGETDANVAK  4.37 1670.9  
FWITNGPDADVLIVYAK  4.21 1922.2  
QLGNLGVLGITAPVQYGGSGLGYLEHVLVMEEISR  4.75 3671.2  
IPAANILGHENK  6.75 1276.5  
DITDHMDR  4.41 1002.1  
LEQNGSPLGRGR  9.6 1283.4  
LGCQEEGAAEVK  4.25 1233.4  
EVEELILTESK  4.09 1289.5  
AVEILADIIQNSTLGEAEIER  6.05 992.1  
SPAGLQVLNDYLADK  4.21 1603.8  
ADEGISFR  4.37 894.0  
LIFKPDLTLEEVQAENPK  4.41 2084.4  
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Peptide sequence pI MW 
IEPLSPELVAAASAVADSLPFDK  3.92 2340.7  
VPINDVLAEDK  4.03 1212.4  
EGICGSCAMNINGGNTLACTRR  5.21 2389.7  
GDVTAQIALQPALK  5.84 1424.7  
SEHPGLSIGDTAK  5.3 1311.4  
GTPEQPQCGFSNAVVQILR  5.99 2044.3  
VNILTRLAAELNK  8.72 1454.7  
GIHSAIDASQTPDVVFASILAAFSK  5.21 2545.9  
ESVNYLVSQQNMLLIPTSFSPLK  6.1 2609.0  
SLLCSLICYR  7.79 1170.5  
ALQDRLVATNLK  8.79 1341.6  
ALWQAAEVERDR  4.68 1443.6  
DGNGTIYPMAKDCMGGIR  5.95 1899.2  
KTASPEDSDMPDHDLEPPR  4.23 2137.3  
DGMTPKGPNHPVQVMPK  8.6 1833.2  
EDPNLVPSISNK  4.37 1312.4  
MKPLWLVYNNK  9.7 1405.7  
DCEGSALLK  4.37 935.1  
ALDAMLDLLK  4.21 1102.4  
ATTDLGRSLGPVELLLR  6.12 1811.1  
DLKLDNLLLDTEGYVK  4.23 1849.1  
TPVTQVNEVTGTLR  5.66 1514.7  
DVEDFLSPLLGK  4.03 1332.5  
IEVEKPFAIAK  6.14 1244.5  
APVTCTPGQPGQQRVLHLELK  8.27 2272.7  
PGIVELPTLEELKVDEVK  4.25 2008.3  
VGAGAPVYMAAVLEYLTAEILELAGNAAR  4.25 2934.4  
DGADIHSDLFISIAQALLGGTAR  4.41 2341.6  
SIVEEIEDLVAR  4 1372.5  
AMGIMNSFVNDIFER  4.37 1744.0  
THTDTESEASILGDSGEYK  4.17 2040.1  
LGAGYPMGPFELLDYVGLDTTK  4.03 2357.7  
EEEAIQLDGLNASQIR  4 1785.9  
QAITQVVVSR  9.75 1100.3  
VVQVVKPHTPLIR  11 1485.8  
KDINNIVK  8.59 943.1  
AAELIANSLATAGDGLIELR  4.14 1998.3  
LAAAFAVSR  9.75 905.1  
CRSGQCVLASR  9.02 1179.4  
LSNTQGVVSAFSTMMSVHR  9.76 2052.4  
AVTAIMTR  9.79 862.1  
ELISNASDALDK  4.03 1275.4  
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Peptide sequence pI MW 
LTLSALIDGK  5.84 1030.2  
VLQHYQESDKGEELGPGNVQK  4.83 2355.6  
TPALVNAAVTYSKPR  9.99 1587.8  
FSLFAGGMLR  9.75 1098.3  
VNLLQIVR  9.72 954.2  
GINTLVTYDMVPEPK 4.37 1677.0 
WVTYFNKPDIDAWELR 4.56 2053.3 
NFSEVFQK  6 998.1  
VPDFSEYR  4.37 1012.1  
AGLVDDFEK  4.03 993.1  
FLQDTIEEMALK  4.14 1437.7  
GTGGVDTAATGGVFDISNLDR  3.93 2023.1  
SEVELVQLVIDGVNYLIDCER  3.83 2406.7  
MPKFSMPSLK  10 1165.5  
VGQGWSYSAVQDIPARR  8.72 1890.1  
HRVSLFGTDAPAVVNCLHILAR  8.27 2389.8  
KPECFGPALRGEGGSGLLAAIEEAIR  4.95 2642.0  
EPGLFDVVIINDSLDQAYAELK  3.77 2449.7  
DIEEIIDELK  3.83 1216.4  
DDTIYEDEDVK  3.66 1341.4  
ELSEALGQIFDSQR  4.14 1592.7  
LDAITDEENDMLDLAYGLTDR  3.57 2383.6  
NLLLSGAQLEASR  6 1371.6  
GPTGVIATTMTDSFLTGQMLLQDLK  4.21 2639.1  
LPNQTHPDVPVGDESQAR  4.54 1960.1  
LEEGPPVTTVLTR  4.53 1411.6  
SEMEMAHLYSLCDAAHAQTEVAKK  5.35 2664.0  
ILLDQVEEAVADFDECIR  3.71 2078.3  
MSVLSLDLTAIK  5.59 1290.6  
VPEFDGKMSVLSLDLTAIK  4.56 2063.4  
KLLTLDMYNAVMLGWAR  8.59 1995.4  
VMVDANEVPIQKMFEK  4.68 1878.2  
LPVPRVSATIQR  12 1336.6  
EILLSADHIIIATGGRPR  6.85 1932.3  
GAAAGQRDYDLLVVGGGSGGLACAK  5.95 2306.6  
APPWVPAMGFTLAPSLGCFVGSR  8.29 2361.8  
SPATVEAQPLPAS  4 1267.4  
GETEELQANACTNPAVHEK  4.48 2041.2  
ATSLGRPEEEEDELAHR  4.41 1939.0  
NASLISALSTGR  9.75 1189.3  
HLFCLYVVSK  8.21 1208.5  
TRLQLQDAGPAR  9.26 1325.5  
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Peptide sequence pI MW 
LPPLPLTLALGAFLNHR  9.76 1843.3  
LTAASVGVQGSGWGWLGFNK  8.75 2035.3  
VPADLGAEAGLQQLLGALR  4.37 1892.2  
FVTHVSDWGALATISTLEAVR  5.32 2273.6  
IYAGQMAVLGR  8.75 1178.4  
AEGSDVANAVLDGADCIMLSGETAK  3.77 2437.7  
IEGTPLETIQK  4.53 1228.4  
LWGLTEMFPER  4.53 1378.6  
Table 1.  List of peptides identified  from mitochondrial fraction by the 
two-dimensional separation strategy. Isoelectric point (pI) and molecular 
weight (MW) of each peptide are provided. Threshold for peptide 
identifications through MASCOT is that the probability of a random match is 
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Figure 16.  pI Range of peptides from different chamber fractions 
The correlation between peptide pI and chamber pH defined by boundary 
immobiline membranes is presented. Each bar shows the pI range of identified 
peptides in each fraction. Fifty percent of the peptides are in the box. The top 
of the box cuts off lowest 25% of the data and the bottom of the box cuts off 
highest 25% of the data. The middle line inside the box shows the median 
value of the data. A horizontal line is connected a small horizontal mark 
(whisker) with the box. The lower whisker represents 1.5×range of the box 
lower than the 25% of the data and the higher whisker represents 1.5×range of 
the box higher than the 75% of the data. The closed dots indicate outliers 








Figure 17. Average pI values of peptides separated from the digest of 
phosphorylase B using cation exchange chromatography (80). A total of 




peptides in the range of pI 7 to 8 (Figure 16), which is in agreement with the 
previous research in our lab (115) and the results from Bundy and coworker, 
who integrated gel based isoelectric focusing with LC-MS/MS and found the 
similar pI distribution for their yeast and E. coli digest peptides (167-168). 
Figure 18 shows the total percentage of peptides identified in each 
fraction. The middle two fractions have the largest number of peptides. Their pI 
range is about from 4 to 8. This is not surprising since only those larger 
peptides have a higher chance of having negatively or positively charged 
amino acids (glutamic acid, aspartic acid or histidine), which make the peptide 
more acidic or basic. These peptide identifications are not necessarily unique 
since there is a small portion of peptides identified in multiple chambers. As 
shown in figure 19, about 80% of the peptides appear in one fraction, and only 
5% peptides present in more than two fractions. This also demonstrates the 
good resolution of sIEF in our research. In addition, it seems that this overlap 
is much smaller than when SCX separation is used as the first dimensional 
separation (80).One change which can be made to further reduce the overlap 
is to wash the HPLC and desalting columns extensively to remove possible 
high abundant peptides leaving in the column, such as going through the same 
gradient elution twice with deionized water before the next fraction is injected. 
As previously mentioned, the analysis of the sample can be repeated 
several times on LC-MS/MS to catch new ions each time, obtain more peptide 














































Figure 18. The percentage of identified peptides in each chamber fraction from 
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Figure 19.  The percentage of identified peptides presenting in a unique 
fraction or in multiple fractions from solution IEF separation 
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cumulative number of identified peptides increased with increasing runs 
(Figure 20). A total of 637 peptides was identified from the two-dimensional 
separation of mitochondrial soluble fraction (Table 1).  
Protein identification and classification 
Each protein was identified based on sequences from identified peptides 
using MASCOT software. The assembling of the unique peptides results in a 
total of 278 distinct proteins identified from 637 peptides in the mitochondrial 
soluble fraction (Table 2). Forty-five percent of the proteins were identified 
based on at least two peptides and for each protein identified with only one 
peptide, then MS/MS spectra was manually checked.  
The proteins are assigned to sub-cellular groups annotated by SwissProt 
database or using Mitoprot (score between 0.8 and 1.0) (169) and PSORT II 
Prediction (170) softwares. Figure 21 shows a graphical representation of the 
subcellular locations of those identified proteins, along with the number of 637 
sequenced peptides that originated from those proteins (Figure 22). Of the 278 
proteins identified, 166, or 60%, have been categorized as mitochondrial 
proteins. There are also many mitochondrial-associated proteins 
identified which are not annotated as mitochondrial proteins by Swissprot or  
other prediction software. For example, galectin-3 binding protein, which is 
annotated by SwissProt as a secreted protein, was reported to be enriched in 
mitochondria and prevent mitochondrial damage and cytochrome c release 
(171-172). Another protein, cathepsin D, which was known to be required for 
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Bax insertion into the mitochondrial outer membrane during the apoptosis 
process (173), is classified as lysosomal protein, however. The list of identified 
proteins in this study may offer evidence for other researchers when they study 
compartmental locations of proteins or specific protein functions.  
The distribution of pI and molecular weight of identified mitochondrial 
proteins is demonstrated in figure 23. More than half proteins have pI greater 
than 7, which is in agreement with the observation from other researches (177), 
and may indicate that cationic properties are needed for import into 
mitochondrial locations (e.g. inner membrane or matrix). It was also found that 
proteins with relatively low molecular weights (<50 kDa) dominate in our 
database, which probably presents another characteristic of the mitochondrial 
proteome. But it should be noted that the values of pI and molecular weight 
reported here are obtained from the protein precursors. The mature forms of 
proteins may undergo posttranslational processing during translocation into 
the mitochondria. 
The protein list was also compared with the work of Dr. Strong, a former 
graduate student of the Fenselau’s group. She studied mitochondrial proteins 
from MCF-7 cell lines using the two-dimensional gel electrophoresis technique 
(174). Figure 24 compares the mitochondrial proteins identified in her study 
and this research. About half of the proteins detected here were analyzed 
using both methods while the other half was not detected with 2D-gel method, 
Many proteins with high pI values, such as cytochrome c (pI: 9.59) and some 
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mitochondrial ribosomal proteins, were not detected using 2D-gels, but were 
found in this study. The pI range of 2D-gel is normally from 3 to 10 and very 
basic proteins are difficult to focus near or beyond the edge of the range. In 
addition, since Dr. Strong used rehydration buffer containing a high 
concentration of urea and detergent to solubilize the mitochondrial pellet, 
many mitochondrial membrane proteins may be extracted and be shown on 
the 2D map even though membrane proteins can not be focused well. It can be 
seen that the shotgun strategy and the traditional 2D gel can be 











Figure 20. The cumulative number of peptides identified in each fraction as a 
function of injection times on LC-MS/MS. Gray bars: numbers of identified 
peptides in different fractions for the first LC-MS/MS analysis; Yellow bars: 
numbers of identified peptides in different fractions for the first two analyses; 








































































Figure 21. Subcellular distribution of the identified proteins from the drug 
susceptible MCF-7 cancer cells. 









Figure 22.  Subcellular distribution of the identified peptides using for those 









































Figure 24  Comparison of the mitochondrial proteins identified in this study 
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O00411 DNA-directed RNA polymerase 9.19 138620 M 1 
O14561 Acyl carrier protein 4.82 17417 M 2 
O15382 Branched-chain-amino-acid aminotransferase 8.88 44288 M 3 
O43497 
Voltage-dependent T-type calcium channel 
alpha-1G subunit  6.14 262472 unknown 3 
O43676 NADH-ubiquinone oxidoreductase B12 subunit  9.19 11271 M 1 
O43837 Isocitrate dehydrogenase [NAD] subunit beta 8.64 42212 M 1 
O60513 Beta-1,4-galactosyltransferase 4 9.18 40041 Golgi 1 
O75311 Glycine receptor alpha-3 chain precursor 8.6 53800 unknown 1 
O75367 Core histone macro-H2A.1 9.8 39486 N 2 
O75390 Citrate synthase 8.45 51712 M 7 
O75438 NADH-ubiquinone oxidoreductase MNLL subunit 9.03 6961 M 1 
O75439 Mitochondrial processing peptidase beta subunit 6.38 54366 M 1 
O75629 CREG1 protein precursor  7.06 24075 M 1 
O75691 Down-regulated in metastasis protein  7.07 318426 N 1 
O75947 ATP synthase D chain 5.22 18360 M 1 
O75964 ATP synthase g chain 9.65 11428 M 1 
O94826 Mitochondrial precursor proteins import receptor 6.75 67455 M 2 
O94925 
Glutaminase, kidney isoform, mitochondrial 
precursor  7.85 73461 M 2 
O95071 Ubiquitin--protein ligase EDD  5.59 309352 unknown 2 
O95202 
Leucine zipper-EF-hand containing 
transmembrane protein 1 6.3 83354 M 1 
O95299 
NADH-ubiquinone oxidoreductase 42 kDa 
subunit 6.87 37147 M 1 
O95613 Pericentrin 2 5.39 378081 unknown 2 
O95831 Programmed cell death protein 8 9.04 66901 M 1 
O96008 
Probable mitochondrial import receptor subunit 
TOM40 homolog  6.79 37893 M 1 
P00367 Glutamate dehydrogenase 1 7.66 61398 M 7 
P00505 Aspartate aminotransferase 9.14 47476 M 4 
P02545 Lamin A/C  6.57 74139 N 3 
P04075 Fructose-bisphosphate aldolase A 8.39 39289 unknown 3 
P04179 Superoxide dismutase [Mn] 8.35 24722 M 1 
P04181 Ornithine aminotransferase 5.72 44808 M 4 
P04406 Glyceraldehyde-3-phosphate dehydrogenase 8.58 35922 C 4 
P04844 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 5.44 69284 ER 1 
P05114 Nonhistone chromosomal protein HMG-14 9.61 10528 N 1 
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P05114 Nonhistone chromosomal protein HMG-14  9.61 10528 N 1 
P05141 
ADP,ATP carrier protein, fibroblast isoform 
(ADP/ATP translocase 2) 9.76 32764 M 1 
P05165 Propionyl-CoA carboxylase alpha chain 6.63 77354 M 1 
P05166 Propionyl-CoA carboxylase beta chain 7.56 58206 M 1 
P05783 Keratin, type I cytoskeletal 18  5.34 47897 keratin 7 
P05787 Keratin, type II cytoskeletal 8 5.52 53573 keratin 11 
P06576 ATP synthase beta chain 5.26 56560 M 10 
P06865 Beta-hexosaminidase alpha chain precursor  5.04 60689 L 2 
P07339 Cathepsin D precursor  6.1 44552 L 2 
P07686 Beta-hexosaminidase beta chain precursor  6.29 63111 L 1 
P07900 Heat shock protein HSP 90-alpha  4.94 84529 C 3 
P07954 Fumarate hydratase 8.85 54637 M 6 
P08238 Heat shock protein HSP 90-beta 4.97 83133 C 1 
P08559 
Pyruvate dehydrogenase E1 component alpha 
subunit 8.35 43296 M 1 
P08727 Keratin, type I cytoskeletal 19 5.04 44079 keratin 4 
P09622 Dihydrolipoyl dehydrogenase 7.59 54150 M 5 
P10109 Adrenodoxin 5.51 19393 M 1 
P10253 Lysosomal alpha-glucosidase precursor  5.62 105338 L 2 
P10412 Histone H1.4 11.03 21734 N 2 
P10515 
Dihydrolipoyllysine-residue acetyltransferase 
component 5.79 65781 M 3 
P10606 Cytochrome c oxidase polypeptide Vb 9.07 13696 M 1 
P10809 60 kDa heat shock protein 5.7 61055 M 29 
P10911 Proto-oncogene DBL 5.72 107673 C 2 
P11047 Laminin gamma-1 chain precursor 5.01 177607 extracellular 1 
P11177 
Pyruvate dehydrogenase E1 component beta 
subunit 6.2 39219 M 3 
P11498 Pyruvate carboxylase 6.37 129634 M 3 
P12532 Creatine kinase 8.6 47037 M 2 
P12956 ATP-dependent DNA helicase II 6.23 69712 N 1 
P13804 Electron transfer flavoprotein alpha-subunit 8.62 35080 M 11 
P13995 
Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase 7.34 34137 M 1 
P14618 Pyruvate kinase, isozymes M1/M2  7.95 57806 M 1 
P14625 Endoplasmin precursor  4.76 92469 ER 1 
P14927 
Ubiquinol-cytochrome c reductase complex 14 
kDa protein  8.75 13399 M 1 
P15586 N-acetylglucosamine-6-sulfatase precursor 8.6 62082 L 1 
P16278 Beta-galactosidase precursor 6.1 76091 L 2 
P16401 Histone H1.5 10.91 22449 N 4 
P16402 Histone H1.3  11.02 22219 N 1 
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P16403 Histone H1.2 10.94 21234 N 1 
P16471 Prolactin receptor precursor  5.23 69506 unknown 1 
P16836 Short chain 3-hydroxyacyl-CoA dehydrogenase 11.61 15909 M 1 
P17317 Histone H2A.z 10.58 13422 N 1 
P18754 Regulator of chromosome condensation 7.18 44969 N 1 
P19367 Hexokinase, type I 6.36 102486 M 2 
P19404 
NADH-ubiquinone oxidoreductase 24 kDa 
subunit 8.22 27392 M 1 
P20674 Cytochrome c oxidase polypeptide Va 5.89 79468 M 2 
P20700 Lamin B1 5.11 66277 N 1 
P21796 
Voltage-dependent anion-selective channel 
protein 1 8.63 30623 M 3 
P21817 Ryanodine receptor 1  5.18 565176 Membrane 3 
P21912 
Succinate dehydrogenase [ubiquinone] 
iron-sulfur protein 9.03 31628 M 1 
P22033 Methylmalonyl-CoA mutase 6.48 83120 M 2 
P22570 NADPH:adrenodoxin oxidoreductase 8.72 53837 M 1 
P22626 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 8.97 37430 N 1 
P22695 
Ubiquinol-cytochrome-c reductase complex core 
protein 2 8.74 48443 M 3 
P23284 Peptidyl-prolyl cis-trans isomerase B precursor 9.33 22742 ER 1 
P23434 Glycine cleavage system H protein 4.91 18911 M 1 
P23528 Cofilin-1 8.26 18371 N/C 1 
P24534 Elongation factor 1-beta  4.5 24633 unknown 1 
P24539 ATP synthase B chain 9.37 28909 M 2 
P24752 Acetyl-CoA acetyltransferase 8.98 45200 M 4 
P25705 ATP synthase alpha chain  9.16 59751 M 5 
P26440 Isovaleryl-CoA dehydrogenase 8.45 46319 M 3 
P26583 High mobility group protein 2  7.77 23903 N 1 
P27695 DNA-(apurinic or apyrimidinic site) lyase 8.42 35423 N 1 
P27695 DNA-(apurinic or apyrimidinic site) lyase 8.42 35423 N 1 
P27708 CAD protein  6.02 242984 C 1 
P28001 Histone H2A.a 11.05 14004 N 1 
P29375 Retinoblastoma-binding protein 2 6.42 195816 N 1 
P29966 Myristoylated alanine-rich C-kinase substrate 4.47 31423 unknown 1 
P30042 ES1 protein homolog 8.5 28170 M 3 
P30044 Peroxiredoxin 5 6.96 16899 M 2 
P30048 Thioredoxin-dependent peroxide reductase 7.68 27693 M 4 
P30049 ATP synthase delta chain 4.53 15019 M 1 
P30084 Enoyl-CoA hydratase 5.88 28354 M 4 
P30405 Peptidyl-prolyl cis-trans isomerase 9.49 22040 M 2 
P30536 Peripheral-type benzodiazepine receptor  9.23 18779 M 1 
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P30837 Aldehyde dehydrogenase X 6.41 57217 M 2 
P31040 
Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit 7.06 72692 M 7 
P31937 3-hydroxyisobutyrate dehydrogenase 8.38 35329 M 3 
P32322 Pyrroline-5-carboxylate reductase 1 7.18 33361 C 1 
P34897 Serine hydroxymethyltransferase 8.76 55993 M 8 
P34947 G protein-coupled receptor kinase 5 8.39 67787 unknown 1 
P35232 Prohibitin 5.57 29804 M 6 
P35270 Sepiapterin reductase 8.25 28048 M 1 
P35579 Myosin heavy chain, nonmuscle type A 5.5 226401 N 1 
P36551 Coproporphyrinogen III oxidase 8.59 50152 M 1 
P36776 Lon protease homolog 6.01 106422 M 5 
P36957 
Dihydrolipoyllysine-residue succinyltransferase  
component 5.89 41349 M 5 
P38117 Electron transfer flavoprotein beta-subunit  8.29 27712 M 4 
P38646 Stress-70 protein 5.87 73681 M 20 
P40926 Malate dehydrogenase 8.92 35531 M 10 
P40939 Trifunctional enzyme alpha subunit 9.16 83000 M 2 
P42126 3,2-trans-enoyl-CoA isomerase 6 28736 M 3 
P42167 
Lamina-associated polypeptide 2, isoforms 
beta/gamma  9.39 50539 N 1 
P42226 Signal transducer and activator of transcription 6 5.84 94135 C 1 
P42338 
Phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit, beta isoform 6.69 122762 unknown 1 
P42704 130 kDa leucine-rich protein  5.49 145201 C 7 
P42765 3-ketoacyl-CoA thiolase 8.32 41924 M 5 
P42785 Lysosomal Pro-X carboxypeptidase precursor 6.76 55800 L 1 
P43897 Elongation factor Ts 8.62 35391 M 2 
P45880 
Voltage-dependent anion-selective channel 
protein 2 6.32 38069 M 2 
P45954 
Acyl-CoA dehydrogenase, short/branched chain 
specific 6.53 47485 M 3 
P46100 Transcriptional regulator ATRX  6.23 282566 C 2 
P46531 
Neurogenic locus notch homolog protein 1 
precursor  4.99 272500 unknown 1 
P47985 
Ubiquinol-cytochrome c reductase iron-sulfur 
subunit 8.55 29652 M 1 
P48047 
ATP synthase oligomycin sensitivity conferral 
protein 9.97 23277 M 1 
P48735 Isocitrate dehydrogenase [NADP] 8.88 50909 M 9 
P49411 Elongation factor Tu 7.26 49542 M 9 
P49419 Aldehyde dehydrogenase family 7 member A1  6.24 55200 M 4 
P49448 Glutamate dehydrogenase 2 8.63 61434 M 2 
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P49748 
Acyl-CoA dehydrogenase, very-long-chain 
specific 8.92 70390 M 5 
P49753 
Peroxisomal acyl-coenzyme A thioester 
hydrolase 2a  8.93 53257 P 2 
P50213 Isocitrate dehydrogenase [NAD] subunit alpha 6.46 39592 M 1 
P50416 Carnitine O-palmitoyltransferase I 8.85 88368 M 1 
P50440 Glycine amidinotransferase 8.26 48455 M 1 
P50897 Palmitoyl-protein thioesterase 1 precursor  6.07 34194 L 2 
P51553 Isocitrate dehydrogenase [NAD] subunit gamma 8.75 42794 M 1 
P51649 Succinate semialdehyde dehydrogenase 8.62 57215 M 2 
P51687 Sulfite oxidase 5.35 53885 M 1 
P51800 Chloride channel protein ClC-Ka  7.62 75285 unknown 1 
P51970 
NADH-ubiquinone oxidoreductase 19 kDa 
subunit  7.93 19974 M 1 
P52564 
Dual specificity mitogen-activated protein kinase 
kinase 6 7.01 37492 unknown 1 
P52815 39S ribosomal protein L12 9.05 21348 M 2 
P53597 Succinyl-CoA ligase [GDP-forming] alpha-chain 9.11 35047 M 1 
P54819 Adenylate kinase isoenzyme 2 7.85 26347 M 1 
P54819  Adenylate kinase isoenzyme 2 7.85 26347 M 1 
P54886 Delta 1-pyrroline-5-carboxylate synthetase 6.66 87302 M 2 
P55084 Trifunctional enzyme beta subunit 9.45 51294 M 1 
P60709 Actin, cytoplasmic 1 5.29 41737 C 4 
P61604 10 kDa heat shock protein 8.91 10801 M 5 
P62736 Actin, aortic smooth muscle 5.24 42009 C 2 
P62805 Histone H4 11.36 11236 N 2 
P62807 Histone H2B.a/g/h/k/l 10.32 13688 N 1 
P62988 Ubiquitin 6.56 8565 N/C 2 
P63104 14-3-3 protein zeta/delta 4.73 27745 C 2 
P63261 Actin, cytoplasmic 2 5.31 41793 C 2 
P68104 Elongation factor 1-alpha 1 9.1 50141 C 1 
P68133 Actin, alpha skeletal muscle  5.23 42051 C 1 
P80404 4-aminobutyrate aminotransferase 8.17 56439 M 7 
P80723 Brain acid soluble protein 1  4.64 22562 N 4 
P82650 Mitochondrial 28S ribosomal protein S22  7.7 41280 M 1 
P82663 Mitochondrial 28S ribosomal protein S25  8.99 20116 M 1 
P82675 Mitochondrial 28S ribosomal protein S5  9.93 48006 M 2 
P82909 Mitochondrial 28S ribosomal protein S36  9.99 11466 M 1 
P82921 Mitochondrial 28S ribosomal protein S21  10.23 10742 M 1 
P84243 Histone H3.3 11.27 15197 N 1 
P99999 Cytochrome c 9.59 11618 M 2 
Q00325 Phosphate carrier protein 9.45 40095 M 1 
Q01826 DNA-binding protein SATB1  6.1 85957 N 1 
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Q02218 2-oxoglutarate dehydrogenase E1 component 6.62 113476 M 3 
Q02252 Methylmalonate-semialdehyde dehydrogenase 8.72 57840 M 4 
Q02338 D-beta-hydroxybutyrate dehydrogenase 9.1 38157 M 2 
Q04837 Single-stranded DNA-binding protein 9.59 17260 M 4 
Q05639 Elongation factor 1-alpha 2 9.11 50470 N 1 
Q06830 Peroxiredoxin 1  8.27 22110 C 1 
Q07021 
Complement component 1, Q subcomponent 
binding protein 4.32 23783 M 3 
Q08257 Quinone oxidoreductase  8.56 35207 C 1 
Q08380 Galectin-3 binding protein precursor 5.13 65331 secreted 3 
Q09666 
Neuroblast differentiation associated protein 
AHNAK  6.29 312493 N 1 
Q10713 
Mitochondrial processing peptidase alpha 
subunit 6.45 58253 M 2 
Q12931 Heat shock protein 75 kDa 8.05 79961 M 4 
Q13011 Delta3,5-delta2,4-dienoyl-CoA isomerase 8.16 35816 M 2 
Q13268 
Dehydrogenase/reductase SDR family member 
2  8.9 27307 N 1 
Q13405 Mitochondrial 39S ribosomal protein L49  9.47 19198 M 2 
Q13535 Serine-protein kinase ATR 7.17 301367 N 1 
Q14061 Cytochrome c oxidase copper chaperone 7.22 6784 M 1 
Q14204 Dynein heavy chain 6.01 532408 C 2 
Q14315 Filamin C 5.68 290959 C 3 
Q14517 
Cadherin-related tumor suppressor homolog 
precursor  4.84 506278 membrane 1 
Q14573 Inositol 1,4,5-trisphosphate receptor type 3  6.04 304038 ER 2 
Q15046 Lysyl-tRNA synthetase 5.94 68048 C 1 
Q16512 Protein kinase N1  5.93 103990 C 2 
Q16595 Frataxin 8.8 23135 M 1 
Q16698 2,4-dienoyl-CoA reductase 9.35 36068 M 3 
Q16740 
Putative ATP-dependent Clp protease proteolytic 
subunit 8.26 30180 M 2 
Q16762 Thiosulfate sulfurtransferase  6.83 33277 M 2 
Q16774 Guanylate kinase  6.11 21594 M 1 
Q16795 
NADH-ubiquinone oxidoreductase 39 kDa 
subunit 9.81 42510 M 1 
Q16822 Phosphoenolpyruvate carboxykinase 6.58 67004 M 6 
Q16836 Short chain 3-hydroxyacyl-CoA dehydrogenase 8.88 34278 M 6 
Q6FI13 Histone H2A.o 10.9 13964 N 1 
Q6P587 
Fumarylacetoacetate hydrolase domain 
containing protein 1 6.96 24843 unknown 1 
Q7Z4W1 L-xylulose reductase  8.33 25913 M 2 
Q7Z589 EMSY protein 9.37 141468 N 1 
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Q86SX6 Glutaredoxin-related protein C14orf87 6.28 16628 M 1 
Q86TX2 
Cytosolic acyl coenzyme A thioester hydrolase, 
inducible  6.9 46277 C 1 
Q8HXP0 Superoxide dismutase [Mn]  6.86 22248 M 1 
Q8IUG5 Myosin XVIIIB  6.49 285185 C 1 
Q8IYE1 Coiled-coil domain containing protein 13 8.93 80854 M 2 
Q8N4Q1 
Coiled-coil-helix-coiled-coil-helix domain 
containing protein 4 4.23 15996 M 1 
Q8N8R3 
Mitchondrial carnitine/acylcarnitine carrier 
protein CACL  9.03 32062 M 1 
Q8TCS8 Polyribonucleotide nucleotidyltransferase 1 7.87 85951 M 2 
Q92523 Carnitine O-palmitoyltransferase I 8.86 87801 M 1 
Q92552 Mitochondrial 28S ribosomal protein S27  5.72 47669 M 1 
Q92665 28S ribosomal protein S31 9.32 45318 M 1 
Q93081 Histone H3/b 11.13 15273 N 1 
Q96EY1 DnaJ homolog subfamily A member 3 9.36 52538 M 1 
Q96EY8 
Cob(I)yrinic acid a,c-diamide 
adenosyltransferase 8.86 27388 M 1 
Q96I99 Succinyl-CoA ligase [GDP-forming] beta-chain 6.15 16511 M 4 
Q96MM6 Heat shock 70 kDa protein 12B 8.81 75688 unknown 1 
Q96RP9 Elongation factor G 1 6.58 83471 M 2 
Q96T58 Msx2-interacting protein  7.35 402248 N 1 
Q99714 3-hydroxyacyl-CoA dehydrogenase type II 7.87 26792 ER 5 
Q99757 Thioredoxin 8.46 18383 M 2 
Q99798 Aconitate hydratase 7.36 85425 M 5 
Q99807 Ubiquinone biosynthesis protein COQ7 homolog 8.77 24307 M 1 
Q99996 A-kinase anchor protein 9  4.95 453667 C 2 
Q9BSD7 Probable UPF0334 kinase-like protein 9.61 20713 unknown 1 
Q9BSH4 UPF0082 protein PRO0477 8.37 32477 M 2 
Q9BSY4 
Coiled-coil-helix-coiled-coil-helix domain 
containing protein 5 6.28 12395 M 1 
Q9BVK6 
Transmembrane emp24 domain containing 
protein 9 precursor  6.67 25105 ER 1 
Q9BWM7 Sideroflexin 3 9.26 35503 M 1 
Q9BX68 Histidine triad nucleotide-binding protein 2  9.2 17162 M 3 
Q9BXB5 Oxysterol binding protein-related protein 10  8.56 83970 N 1 
Q9BXU1 Serine/threonine-protein kinase 31  5.06 115730 unknown 1 
Q9BZZ5 Apoptosis inhibitor 5 5.84 57561 N 1 
Q9H0U6 39S ribosomal protein L18 9.63 20577 M 1 
Q9H2U2 Inorganic pyrophosphatase 2 7.07 37920 M 4 
Q9H4K7 Putative GTP-binding protein 5 9.52 43955 M 1 
Q9H9B4 Sideroflexin 1 9.22 35488 M 2 
Q9H9J2 39S ribosomal protein L44 8.65 37535 M 1 
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Q9H9Q2 COP9 signalosome complex subunit 7b 5.83 29622 N/C 1 
Q9HAV7 GrpE protein homolog 1 8.24 24279 M 3 
Q9HCC0 Methylcrotonoyl-CoA carboxylase beta chain 7.58 61333 M 4 
Q9NNW7 Thioredoxin reductase 2 7.23 56460 M 2 
Q9NP81 Seryl-tRNA synthetase 8.35 58283 M 1 
Q9NRC6 Spectrin beta chain, brain 4 6.23 416835 C 2 
Q9NS69 
Mitochondrial import receptor subunit TOM22 
homolog 4.27 15390 M 1 
Q9NZE8 39S ribosomal protein L35 11.8 19212 M 1 
Q9NZJ6 
Hexaprenyldihydroxybenzoate 
methyltransferase 7.12 10998 M 1 
Q9P0J1 
[Pyruvate dehydrogenase 
[Lipoamide]]-phosphatase 1 6.2 61054 M 2 
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase 7.01 35668 M 1 
Q9UFN0 NipSnap3A protein  9.21 28467 C 1 
Q9UGV6 High mobility group protein 1-like 10 6.99 24218 N 2 
Q9UIJ7 GTP:AMP phosphotransferase mitochondrial  9.16 25434 M 1 
Q9UJ96 
Potassium voltage-gated channel subfamily G 
member 2 8.33 51240 unknown 1 
Q9UJZ1 Stomatin-like protein 2  6.87 38534 M 1 
Q9UN73 Protocadherin alpha 6 precursor 4.93 102716 secreted 1 
Q9UPY3 Endoribonuclease Dicer  5.45 217628 N 1 
Q9UQE7 Structural maintenance of chromosome 3 6.77 141542 N 1 
Q9Y277 
Voltage-dependent anion-selective channel 
protein 3 8.84 30659 M 1 
Q9Y3E5 Peptidyl-tRNA hydrolase 2 8.95 19194 M 1 
Q9Y4A5 
Transformation/transcription domain-associated 
protein  8.49 437600 N 1 
Q9Y5Q5 Atrial natriuteric peptide-converting enzyme  4.87 116565 unknown 1 
Q9Y676 28S ribosomal protein S18b 9.47 29396 M 2 
Q9Y6C9 Mitochondrial carrier homolog 2 8.25 33331 M 1 
 
Table 2. Proteins identified in the mitochondrial fraction. SwissProt accession 
numbers are provided. Subcellular location abbreviation: M-mitochondira, 
C-cytosol, N-nucleus, L-lysosome, ER-endoplasmic reticulum. The isoelectric 
point (pI), molecular weight (MW) and evaluation of the reliabilities of 
identification of each protein are provided.
 107
Integration of 18O labeling with solution isoelectric focusing (sIEF) 
Since two 18O atoms can be incorporated into a peptide C-terminus 
resulting in a mass difference of 4 Da, quantitiation of mitochondrial proteins 
can be achieved by enzyme-catalyzed 18O labeling of mitochondrial peptides, 
coupled with efficient separation strategy and a mass spectrometer with 
adequate resolution.  
Quantitative proteomics was evaluated using a model protein, lysozyme 
from chicken egg white. Lysozyme (200μg) was digested and labeled with 
H216O or H218O both in the presence of immobilized trypsin. The use of 
immobilized trypsin allowed for a highly efficient catalysis because the enzyme 
concentration can be very high and trypsin autolysis will be minimized (175). 
The extent of labeling at room temperature and 37℃ was examined. Using 
MALDI-TOF/MS, figure 25 presents the spectra of singly charged lysozyme 
peptide WWCNDGR with a molecular weight of 933.3 Da. Panel A shows the 
isotopic distribution of this unlabeled peptide. There is a 4 Da shift between 
panel A and panel B, which means the peptide was labeled with two atoms of 
18O. The sample in panel C was labeled under the same conditions as panel B, 
except that the labeling process took place at 37℃ for 5 hours instead of room 
temperature for 10 hours. It can be seen that there is incomplete labeling in 
panel B even after 10-hour labeling while there are no detectable 16O peaks in 
panel C. This indicates that the choice of 37℃ was more efficient for 18O 



























































Figure 25.  MALDI-TOF mass spectra of the singly-charged peptide 
WWCNDGR (carbamidomethylated). A: the isotopic distribution of the 
unlabeled peptide with monoisotopic peak at m/z 993.3. B: Peptide labeled by 
18O at room temperature for 10 h. C: Peptide labeled by 18O at 37℃ for 5 h.
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selected 37℃ and 5 h as the labeling condition for subsequent studies. 
Molar equivalents of labeled and unlabeled lysozyme peptides were then 
combined and analyzed using MALDI-TOF mass spectrometry. Figure 26 
presents the peptide mass map of the mixture of labeled and unlabeled 
lysozyme peptides. Enlarged partial spectra of singly-charged peptides 
WWCNDGR and FESNFNTQATNR are shown in figure 27. The isotopic ratio 
of 18O/16O was calculated from each monoisotopic labeled and unlabeled peak 
area, which should be very closed to the results calculated from equation 1 
(see Experimental part). Table 3 lists the theoretically and experimentally 
digested peptides. The average ratio (18O/16O) from all detected peptide pairs 
is 0.97, in agreement with the mixing ratio.  
Next, 18O labeling was integrated with solution isoelectric focusing and 
capillary LC-tandem mass spectrometry to study changes in mitochondrial 
proteins associated with drug resistance in MCF-7 human cancer cells. The 
overall scheme of sIEF and LC-MS/MS analysis of 16O/18O labeled 
mitochondrial peptides from MCF-7 cells is shown in figure 28. Briefly, the 
proteins were extracted from mitochondrial pellets of MCF-7 drug susceptible 
and drug resistant cells and digested into peptides separately. The resultant 
peptides were 16O/18O labeled (drug resistant sample labeled by 18O and drug 
susceptible sample labeled by 16O). The pooled sample (1:1) was fractionated 
by solution IEF and then each fraction was submitted for nanoLC-ESI-TOF 
analysis for protein quantitative study.  
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Figure 26.  MALDI-TOF mass spectrum of MS scan of digested labeled and 









993.4 WWCNDGR yes 0.94 
1045.5 GTDVQAWIR yes 0.96 
1325.6 GYSLGNWVCAAK yes 0.95 
1428.6 FESNFNTQATNR yes 1.02 
1675.8 IVSDGNGMNAWVAWR yes 1.00 
1754.8 NTDGSTDYGILQINSR yes 0.95 
2508.2 NLCNIPCSALLSSDITASVNCAK no N/A 
 
Table 3. The theoretical and observed tryptic-digested lysozyme peptides and 






Figure 27.  Mass spectra of isotope pairs of two digested lysozyme peptides 
recorded on a MALDI-TOF mass spectrometer. A: isotope pair of peptide 
WWCNDGR with monoisotopic unlabeled peak at 993.0. B: isotope pair of 
peptide FESNFNTQATNR with monoisotopic unlabeled peak at 1428.2. The 
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Figure 28.  Overall scheme of integration of 18O labeling strategy with sIEF for 
comparative proteomics. 
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Extensive peptide MS/MS fragmentations were obtained for the most 
three abundant MS peaks from each MS scan during an LC run. Peptides, and 
thus proteins, were first identified from all those MS/MS scans. The 
experimental peak areas for the isotopic peaks of peptides were derived from 
the reconstructed mass spectra of the MS scans across the chromatographic 
peaks. In order to account for single incorporation of an 18O atom at the 
C-terminus of a peptide and to obtain more accurate ratio measurements, the 
theoretical isotopic distribution for each peptide can be obtained based on its 
sequence using the MS-isotope program (166). Those measured and 
theoretical peak areas were then used to determine the relative ratio of 16O 
and 18O quantities for each peptide isotope pair using equation 1 (shown in 
Experimental part). Finally, the overall ratio of a protein was calculated from an 
average of all identified peptide ratios. We usually consider the ratio of 16O/18O 
lower than 0.5 or higher than 2.0 to be a significant change biologically. The 
majority of the identified proteins did not show altered abundances in 
mitoxantrone-resistant MCF-3 cells. Figure 29 shows partial mass spectra of 
peptides from the stress-70 protein as an example of those proteins whose 
abundances do not change. The partial MS spectra of the isotopic pairs of 
doubly-charged labeled and unlabeled peptides TTPSVVAFTADGER and 
DAGQISGLNVLR are presented in panel A and B respectively. Each labeled 
and unlabeled peptide pair co-eluted from the LC and appeared as isotopic 
doublets with 2 Da apart in the mass spectrum. These two peptides are both 
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identified as belonging to mitochondrial protein stress-70 protein. Figures 30 
and 31 illustrate partial MS spectra of peptides from two proteins that have 
altered abundances. They show the increase in the abundance of elongation 
factor Tu by 2.3 fold and the decrease in the abundance of dihydrolipoyl 
dehydrogenase by 2.2 fold, respectively.  
It was noted that there is some suppression of peaks immediately to the 
right of intense peaks in the spectrum of isotopic envelope of peptide. For 
example, in figure 32, the isotope distribution of +2 charge state of unlabeled 
peptide SDLAVPSELALLK is distorted by a high ion count. The first and 
second 13C isotopic peak (A) was lower than expected by comparison with the 
theoretical isotope envelope (B). This is a detector saturation effect, which 
happened when the detector is saturated by high ion counts in a certain 
situation. One of the results is that when two ions reach the detector in 
sequence within a short interval, some suppression of the second ion count 
happens because of the detector saturation by the first intense ion (176). Most 
mass spectrometer instruments have a correction program to minimize this 
saturation effect. But we still encountered some of these problems in our 
spectra. But fortunately, this detector saturation effect will not affect our results 
significantly, because only the monoisotopic peak and the peak with masses 2 
Da higher are required for relative quantitation calculation for each labeled and 











Figure 29.  Partial ESI-TOF mass spectra of two peptides from stress-70 
protein. Isotopic pairs of the unlabeled peptide from the mitoxantrone resistant 
cell line (MX) and the 18O labeled peptide from the drug susceptible cell line 
(WT) are shown. A: the isotopic pair of the doubly-charged peptide 
TTPSVVAFTADGER. B: the isotopic pair of the doubly-charged peptide 


























Figure 30.  Partial ESI-TOF mass spectra of two peptides from mitochondrial 
protein elongation factor Tu. Isotopic pairs of the unlabeled peptide from the 
mitoxantrone resistant cell line (MX) and the 18O labeled peptide from the drug 
susceptible cell line (WT) are shown. A: the isotopic pair of the doubly-charged 
peptide GEETPVIVGSALCALEGR. B: the isotopic pair of the doubly-charged 



































Figure 31.  Partial ESI-TOF mass spectra of two peptides from dihydrolipoyl 
dehydrogenase protein. Isotopic pairs of the unlabeled peptide from the 
mitoxantrone resistant cell line (MX) and the 18O labeled peptide from the drug 
susceptible cell line (WT) are shown. A: The isotopic pair of the 
doubly-charged peptide SEEQLKEEGIEYK. B: the isotopic pair of the 
triply-charged peptide NETLGGTCLNVGCIPSK (carbamidomethylated). The 

































Figure 32.  Experimental and theoretical isotope pattern of peptide 
SDLAVPSELALLK.  A. Partial spectrum recorded by ESI-TOF. B. Theoretical 
isotope distribution of this peptide calculated and visualized by MS-Isotope 
program (166). The tables on the right side show the relative peak area for 
each isotopic peak. 



















Evalution of forward and reverse 18O labeling 
To achieve accuracy and reproducibility in protein quantitation by mass 
spectrometry, a reverse labeling method was proposed by Wang et al 
(178-179). This strategy has also been evaluated in the present project. In the 
labeling process shown in figure 28, referred to as forward labeling, peptides 
stemming from drug susceptible MCF-7 cells were labeled in H218O. In the 
reverse labeling method, conversely, the peptides stemming from drug 
resistant cells were labeled with 18O. The two inverse labeling experiments 
were performed in parallel. Each peptide mixture was fractionated and 
analyzed by the same strategy as previously described. As a result, an 
inverted labeling pattern will be produced between the two parallel 
experiments. For example, figure 33 shows MS scans from the inverse 
labeling experiments. The characteristic pattern of a 2 Da mass shift for 
doubly-charged ions can be seen from both spectra. The signal intensity ratios 
(16O/18O) are approximately reciprocal between two labeling strategies. It is not 
possible to get 100% complete labeling for every peptide in the mixture, for 
example, different peptide might have different 18O exchange rate. Thus 
reverse labeling strategy is expected to reduce such ambiguity in data 
interpretation, especially for some short peptides, whose mass spectra do not 
typically provide unambiguous completion of labeling (150). In addition, 
reverse labeling experiment is especially useful for those situations where a 
protein is only detected in one sample while not in the other. Figure 34 and 35 
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are examples that demonstrate this benefit. Two peptides ELSEALGQIFDSQR 
and SDLAVPSELALLK both originate from galetin-3 binding protein precursor. 
In each forward labeling experiment, 18O labeled peptides from drug 
susceptible cells were not detected in MS scans. This phenomenon was 
confirmed by the reverse labeling process, where those undetected peptides 
(labeled with 16O this time) were not found either. It should be noted that the 
dynamic range of measuring 16O/18O in our mass spectrometer is about 10:1. A 
low abundant protein with the dynamic range beyond 10 will behave as an 
undetected protein in our study. 
In addition, the double experiments can provide identification of additional 
peptides and thus proteins. An example is shown in figure 36 with two tandem 
mass spectra of a peptide from two inverse labeling experiments. This peptide 
was not detected in drug susceptible cells, thus there were only MS/MS 
spectra for peptides from drug susceptible cells (16O coded in forward labeling 
and 18O coded in reverse labeling) for both experiments. Tandem mass 
spectrum from forward labeling was submited to database search to identify 
the peptide sequence (ELSEALGQIFDSQR) and its original protein (galetin-3 
binding protein). The peptide from reverse labeling was not identified due to 
the y-ion mass shift by 4 Da. By comparing the two tandem mass spectra, it 
can be confirmed that they characterized the same peptide. 
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Forward 18O labeled
Reverse 18O labeled 















Figure 33.  Partial MS spectra of the same peptide pair from two inverse 
labeling experiments. This doubly-charged peptide was identified as 
SEEQLKEEGIEYK, originating from mitochondrial protein: dihydrolipoyl 
dehydrogenase.  A: In the forward labeling procedure, peptides stemming 
from drug susceptible cells (WT) were labeled with 18O. B: In the reverse 
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Figure 34.  Partial MS spectra of the same peptide pair from two inverse 
labeling experiments. The peptide was identified as ELSEALGQIFDSQR, 
originating from mitochondrial protein: galectin-3 binding protein. This peptide 
is not detected in WT cells in either labeling experiments. The insets show the 
fraction chamber where the peptide presented in the sIEF separation and its 
elution time from LC-MS. 
pH: 3-5 
elution time: 43.6min 
pH: 3-5 





















Figure 35.  Partial MS spectra of the same peptide pair from two inverse 
labeling experiments. The peptide was identified as SDLAVPSELALLK, 
originating from mitochondrial protein: galectin-3 binding protein. This peptide 
is not detected in WT cells in either labeling experiments. The insets show the 
fraction chamber where the peptide presented in the sIEF separation and its 
elution time from LC-MS. 
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Figure 36. Tandem mass spectra of precursor peptide ELSEALGQIFDSQR 
from two inverse labeling experiments. This peptide was not detected in drug 
susceptible cells. Thus MS/MS spectra are obtained only for peptides from 
drug susceptible cells (16O coded in forward labeling and 18O coded in reverse 




Mitochondrial protein abundance profile in the MCF-7 cell line resistant 
to mitoxantrone 
Forward and reverse 18O labeling experiments integrated with solution 
isoelectric focusing and LC-MS were used to compare the protein abundance 
profiles between the drug-susceptible MCF-7 cell line and the cell line selected 
for resistance to mitoxantrone. For each harvest (including three-replicate 
LC-MS runs after solution IEF), ratios from several peptides and different 
replicates from the same proteins of the origin were averaged. Three ratios for 
the same protein from three harvests were averaged again to obtain the final 
ratio and standard deviation for each protein. Table 4 lists the proteins that 
show alterations in their abundance profiles between these two cell lines. It 
can be seen that for some proteins, there are differences in ratios between 
forward labeling and reverse labeling experiments. This observation may be 
partially due to the incomplete labeling for some specific peptides which may 
need extended time for 18O labeling. That is also an important benefit from 
performing the reverse labeling experiments, which can reduce such ambiguity 
from incomplete labeling in data interpretation. 
It is obvious that efficient software should be developed for the task of 
data analysis and interpretation in both the identification and quantitation 
processes. For example, the same peptide from different experiments could be 
matched according to its physical properties (e.g. elution time, pI) or its MS 
and MS/MS spectra. Those peptides can then be further quantitated based on 
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Table 4.  Proteins with altered abundances between the mitoxantrone resitant 
(MX) and drug susceptible (WT) MCF-7 cell lines analyzed using both forward 
and reversed labeling experiments. Only changes >2 are considered 
significant. The average and standard deviation of each ratio are calculated 



















P35232 Prohibitin 2.9±0.3 2.4±0.1 
P82650 




Mitochondrial 28S ribosomal protein 
S31 
3.3±0.5 2.5±0.5 
Q9BZZ5 Apoptosis inhibitor 5 3.3±0.6 2.4±0.2 
P20674 Cytochrome C oxidase polypeptide Va 3.5±0.6 2.0±0.4 
Q16698 2, 4-dienoyl-CoA reductase 3.6±0.3 2.1±0.1 
Q08380 Galectin-3 binding protein precursor 
Only present in 
MX 
Only present in 
MX 
P09622 Dihydrolipoyl dehydrogenase 0.5±0.1 0.4±0.1 
Q9HAV7 GrpE protein homolog 1 0.5±0.1 0.4±0.1 
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Biological implications of abundance changes 
The proteins summarized in table 4 can be classified into seven sets 
according to their known or predicted functions based on published literature, 
as well as from the mitochondrial protein resource: the MitoProteome 
database (180): 
1. Cell death, defense, rescue and aging (including apoptosis) 
 Apoptosis inhibitor 5 
 Prohibitin 
 Galectin-3 binding protein precursor 
2. Fatty acid metabolism 
 2, 4-dienoyl-CoA reductase 
3. Oxidative phosphorylation (OXPHOS) 
 Cytochrome C oxidase polypeptide Va 
4. Tricarboxylic acid cycle (TCA) cycle 
 Dihydrolipoyl dehydrogenase 
5. Protein synthesis 
 Mitochondrial 28S ribosomal protein S22 
 Mitochondrial 28S ribosomal protein S31 
 Elongation faction Tu 
6. Amino acid metabolism 
 Delta 1-pyrroline-5-carboxylate synthetase 
 Methylcrotonoyl-CoA carboxylase beta chain 
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7. Transport: 
 GrpE protein homolog 1 
The goal of this study was to identify the proteins with altered abundances 
between the two cell lines. Here we consider the biological implications of 
these abundance changes, which might elucidate possible mechanisms for 
resistance to mitoxantrone in MCF-7 cells (MX MCF-7). 
Apoptosis 
As previously described, most chemotherapeutic agents kill cancer cells 
by inducing them to undergo apoptosis (14, 45). Mitoxantrone is also known to 
be a potent inducer of apoptosis in MTLn3 breast cancer cells (181). Blocking 
apoptosis contributes an important mechanism of drug resistance (15-17). In 
our studies, three proteins which can be involved in apoptosis were observed 
to have higher abundances in the cells resistant to mitoxantrone: prohibitin, 
galectin-3 binding protein and apoptosis inhibitor 5.  
Galectin-3 binding protein, also known as Mac-2 binding protein, was 
originally described as a tumor-secreted antigen in human breast cancer cells 
(182) and then reported to participate in the immune defense against cancer 
and other pathogens (183). It binds to galectins (e.g. galectin 1 and 3), 
collagens and fibronectin and may relate to cell-cell and cell-extracellular 
adhesion (184). Galectins and their binding ligands have been implicated to 
play a role in cancer metastasis and their abundance may correlate with 
survival of cancer patients (184-186). Experimental data showed that patients 
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with lymphoma who have high galecin-3 binding protein levels displayed 
significantly lower responses to chemotherapy than did patients with low levels 
of this protein (187). There are few reports elucidating the mechanism and 
subcellular location of galectin-3 binding protein. But extensive studies have 
been carried out for its most important receptor, galectin-3, which is a member 
of the β-galactoside-binding lectin family (188). Galectin-3 was reported to 
regulate tumor proliferation, angiogenesis and apoptosis and has shown 
antiapoptotic function in certain cell types (189-190). There is a report 
demonstrating that galectin-3 is translocated to the perinuclear mitochondrial 
membranes from the cytoplasm and inhibits cytochrome c release following a 
variety of apoptotic stimuli (191). It has already been suggested that galectin-3 
may confer chemotherapy and apoptosis resistance (192-194). In our research 
galectin-3 binding protein was found in the MX MCF-7 cell line but was not 
detected in the drug susceptible cell line. This may suggest that galectin-3 
binding protein is upregulated in MX cells, contributes to apoptosis evasion 
and allows the cells survive. Unfortunately, galectins, including galectin-3 were 
not detected in our studies. Further work could target these specific proteins. 
We also observed a significant increase in the abundance of apoptosis 
inhibitor 5 (API-5) in MX cells. API-5 was originally recognized as a putative 
nuclear inhibitor of apoptosis and has been little-studied so far. It was shown 
that both the levels of API-5 mRNA expression and its protein were higher in 
some cancer cells and the effect of API-5 on cultured cervical cancer cells was 
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associated with antiapoptotic process (195-197). More recently, API-5 was 
revealed to be a potent suppressor of E2F-dependent apoptosis (198). 
E2-promoter binding factor (E2F) family members are not only involved in cell 
proliferation, but also sensitize cells to apoptosis. The latter effect is 
associated with E2F1 protein (199). It was also found that E2F1 
overexpression is related to a mitochondrial pathway to induce cell death (200). 
E2F-induced apoptosis causes the release of mitochondrial 
apoptosis-inducing factor (AIF), which can induce chromatin condensation and 
DNA fragmentation. As a suppressor of E2F, API-5 may also be present in 
mitochondria in cancer cells. Based on these conclusions and our data, in 
which we see an increased abundance of API-5 in MX cells, we suggest that 
DNA damage, caused by the inhibition of topoisomerase II by mitoxantrone 
drug initiates E2F-dependent apoptosis in MCF-7 cells. In the drug resistant 
cells higher abundance of apoptosis inhibitor 5 deregulates E2F -1 activity thus 
blocking E2F-dependent apoptosis pathway.  
Prohibitin is the third protein relating to apoptosis whose abundance was 
found here to be increased in MX cells. The best-described function of 
prohibitin is as a chaperone protein in the mitochondria to stabilize newly 
synthesized subunits of mitochondrial respiration enzymes (201). Prohibitin 
also plays a role as a tumor suppressor and a regulator protein in apoptosis 
(202). It has been shown that over-expressed prohibitin in human B cells 
prevented apoptosis induced by the topoisomerase I inhibitor, camptothecin 
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(203). The same author also reported that prohibitin played a protective role in 
breast cancer cells treated with chemotherapy drugs and suggested that it 
could be used to determine the chemosensitivity of cancer cells. They later 
suggested that prohibitin regulated E2F function as a suppressor in the 
apoptotic pathway, and that it may also interact with p53, which is an important 
apoptotic inducer in the nucleus (204). A significant portion of prohibitin, which 
was co-localized with both E2F1 and p53, was found to be localized in the 
nucleus of MCF-7 cells and it remained in cytoplasm after apoptosis induced 
by camptothecin. An earlier study in our lab also showed that prohibitin was 
present in the nuclear fraction of MCF-7 cells (205) and was detected with an 
increased abundance in MX MCF-7 cells. The literature, together with our 
observations, indicates that prohibitin is up-regulated and acts as an 
anti-apoptotic factor in drug resistance. 
We should also notice that since chemoresistance may be multi-factorial 
(7-8), the destiny of the cancer cell after chemotherapeutic treatment is a result 
of the overall apoptotic capacity of that cell. Several factors are expected to be 
involved in the pro-apoptotic or anti-apoptotic pathways in drug resistance 
mechanism. 
Fatty acid oxidation 
Fatty acid oxidation (β-oxidation) occurs in mitochondria, where fatty acid 
molecules are degraded through the sequential removal of two carbon units by 
oxidation at the β-carbon position of the fatty acyl-CoA molecules. Each 
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round of β-oxidation produces NADH, FADH2 and acetyl-Co A molecules. 
Acetyl-Co A will then enter TCA cycle, where it is further oxidized to CO2 with 
generation of NADH, FADH2 and ATP molecules. Those NADH and FADH2 
molecules from both fatty acid oxidation and the TCA cycle may enter the 
respiratory pathway for the production of ATP. In our work with the MX MCF-7 
cell line we detect an increased abundance of a key enzyme involved in fatty 
acid oxidation, 2, 4-dienoyl –CoA reductase.  
The degradation of unsaturated fatty acids, which generally contain cis 
double bonds, requires auxiliary enzymes in addition to the enzymes 
necessary for oxidation of saturated fatty acids. 2, 4-Dienoyl –CoA reductase is 
a key mitochondrial enzyme in the metabolism of unsaturated fatty acids. It 
catalyzes 2,4-dienoyl-CoA to yield trans-3-enoyl CoA, which is then converted 
into trans-2-enoyl CoA by 3,2-trans-enoyl CoA isomerase, a common 
intermediate in the β-oxidation of saturated fatty acids. An increase in 2, 
4-dienoyl –CoA reductase has not been previously associated with drug 
resistance. It should be noted that some other enzymes involved in fatty acid 
oxidation were identified in our studies, but were not detected to be changed. 
Warburg proposed in 1930 that cancer cells rely on the glycolytic pathway to 
convert glucose to ATP (206). It was first demonstrated by proteomics that 
elevated glycolysis occurred in renal cancer tissue (207). Furthermore, fatty 
acid oxidation has been shown to be reduced in cancer cells (208). The 
molecular mechanism of this less efficient metabolic phenotype in cancer cells 
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is still under debate. Some authors support the view that the phenotype shift to 
glycolysis results from a damaged mitochondrial function which includes 
energy transduction (209-211). This damage may be due to frequent 
mitochondrial DNA mutation in cancer cells. In addition, since the mitochondrial 
respiration chain is the major endogenous source of reactive oxygen species 
(212), which may damage DNA and promote apoptosis, alteration to high-rate 
but inefficient glycolysis to produce ATP has been proposed to protect newly 
synthesized and exposed DNA in cancer cells.On the other hand, a report has 
demonstrated that there is higher use of fatty acids for fuel in mitochondria, 
accompanied by a higher rate of cytosolic glycolysis in various drug-resistant 
cancer cells than in drug-susceptible cancer cells (213). These authors 
suggested that drug-resistant cells may be better at repairing damage induced 
by ROS. Taking these observations and our data into consideration, we 
suggest that the increase in 2, 4-dienoyl –CoA reductase supports the higher 
use of fatty acid by drug resistant MCF-7 cells.  
Oxidative phosphorylation 
As a cell’s energy factory, mitochondria play a crucial role in the 
production of high-energy phosphate ATP. During oxidative phosphorylation, 
electrons are transferred from NADH (or FADH2) to molecular oxygen, 
eventually forming H2O. A series of protein complexes located in the inner 
mitochondrial membranes are involved in this process. Meanwhile protons are 
pumped from the mitochondrial matrix into intermembrane space as a result of 
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this flow of electrons. The final phase of oxidative phosphorylation is carried 
out by ATP synthase (complex V), synthesizing ATP from ADP, which is driven 
by the flow of protons back into the mitochondrial matrix.  
Cytochrome C oxidase (COX) is the terminal complex of the 
electron-transport chain and transfers electrons from reduced cytochrome C to 
molecular O2, forming water. This is the rate determining step of the electron 
transport chain (214). The COX complex is composed of 13 subunits, three of 
them (I, II, III) comprise the catalytic core of the enzyme and are all coded by 
mitochondrial DNA. The function of the remaining ten subunits (including Va 
and Vb), which are encoded by nuclear DNA, has not been well studied. More 
recently, it was suggested that COX might act as a molecular switch that 
induces apoptosis under energy stress conditions (215-216). They found that 
decreased expression of COX subunit I was significantly related to apoptosis 
resistance. Other researchers found that the concentration ratio of nuclear 
encoded COX subunits to mitochondrial encoded subunits was increased in 
prostate cancer compared to normal cells (217-218). The authors implied that 
this increase may lead to altered metabolism in cancer cells. But how this ratio 
alteration might interfere with chemotherapy has not been studied yet. 
Cytochrome C oxidase Va subunit was detected to increase in abundance in 
MXR cells in our study. This alteration of the COX subunit ratio may also 
indicate alterations in metabolism pathways in drug resistant cells. It should be 
noted that some other nuclear-encoded subunits, such as COX Vb, were 
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identified in our study but were not found to be changed. 
Tricarboxylic acid cycle (TCA)  
The central function of TCA is the oxidation of acetyl-CoA to CO2 and H2O. 
Acetyl-CoA is derived from the metabolism of fuel molecules such as fatty acid 
and carbohydrates. This oxidation accounts for about two thirds of the total 
oxygen consumption and ATP production in humans. The citric acid cycle also 
participates in some important synthetic reactions, such as amino acid 
synthesis. 
As the starting point of TCA cycle, the formation of acetyl-CoA from glycolysis 
is less direct than from fatty acid oxidation. The pyruvate from glycolysis is 
transported into the mitochondria matrix, where pyruvate is oxidatively 
decarboxylated by the pyruvate dehydrogenase complex (PDH). This 
irreversible reaction is the key link between glycolysis and the citric acid cycle. 
PDH is a large, highly integrated complex of three kinds of enzymes: pyruvate 
dehydrogenase component (E1), dihydrolipoyl transacetylase (E2) and 
dihydrolipoyl dehydrogenase (E3). It has been demonstrated that the flavin of 
the dihydrolipoyl dehydrogenase (Dld) component, which is abundant in 
mitochondria and has a sufficient redox potential to allow for superoxide 
production, can generate superoxide (219-220). More recently, there is a 
report detecting Dld as a source of reactive oxygen species when there is 
limited glucose (221). They suggested Dld instead of the electron transport 
chain as the main ROS source when glucose is limited. Taking these 
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observation and previous information together with our data that E3 has a 
decreased abundance in MX cells, we consider that MX cells may have an 
impaired TCA cylcle as well as a lower rate of respiration. Together, these 
reduce ROS and prevent mitoxantrone-induced cytotoxicity. 
Protein synthesis 
Mitochondrial DNA (mtDNA) encodes 13 polypeptides, each of which is a 
subunit of one of four respiratory enzyme complexes localized to the inner 
mitochondrial membrane. They include seven subunits of respiratory enzyme 
complex I, one subunit of complex III, three subunits of complex IV, and two 
subunits of complex V. Since these proteins that are essential to oxidative 
phosphorylation have high hydrophobicity, nuclear synthesis and cytoplasmic 
transport are precluded.  
Mitochondrial ribosome is the factory for synthesis of 
mitochondrial-encoded proteins. It is a ribonucleoprotein particle made of a 
small (28S) and a large subunit (39S). It was discovered that the key sites in 
the ribosome are composed almost entirely of RNA and contributions from the 
ribosomal proteins are minor. Many of the proteins having elongated structure 
extending into the rRNA core to stabilize its structure, and they may play a role 
in streamlining the process of protein synthesis (222). The amino acid 
sequence is known for 30 proteins in the small subunit and 48 proteins in the 
large subunits. We detected 13 (16%) out of those 78 proteins. Two of them 
have increased abundance in MX cells, mitochondrial 28S ribosomal protein 
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S22 and mitochondrial 28S ribosomal protein S31. It has been reported that 
two proteins, death-associated protein 3 and PDCD 9, known to be involved in 
promoting apoptosis in mammalian cells have been identified as mitochondrial 
ribosomal proteins (223). But their precise function is not known. The authors 
suggested that components of the mitochondrial proteins’ biosynthetic system 
might play a pivotal role in apoptosis. How the ribosomal protein might function 
in cancer drug resistance needs further investigation. 
Elongation factors are a set of proteins that facilitate the translational 
elongation, including the formation of all peptide bonds. Elongation factor Tu 
(EF-Tu) is responsible for the selection and binding of the aminoacyl-tRNA and 
GTP to the active site of the ribosome. After binding, GTP is hydrolyzed to 
GDP and released from the ribosome with EF-Tu. Elongation factor Ts (EF-Ts), 
a second elongation factor, joins the EF-Tu complex and induces the 
dissociation of GDP. Once EF-Tu binds to another GTP, EF-Ts is concomitantly 
released. There are few studies associating EF-Tu with cancer. One report 
stated that a mitochondrial elongation factor-like protein is over-expressed in 
tumors (224). That protein has 50-70% homology to eukaryotic-EF-Tu. Our 
observation of a higher abundance of EF-Tu in MX cells might relate to the 
increase of the protein translation rate, which might be associated with drug 
resistance in an indirect way. 
Amino acid metabolism 
The primary uses of amino acids are as building blocks for protein and 
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peptide synthesis and as a source of nitrogen for the synthesis of other amino 
acids. Amino acids in excess of those needed for biosynthesis are used as 
metabolic fuel through catabolism. There are two proteins, which are detected 
to have increased abundance in MX cells here that are enzymes in proline 
biosynthesis and leucine catabolism, respectively.  
Delta1-pyrroline-5-carboxylate synthetase is located in the mitochondrial 
inner membrane, where it catalyzes the ATP and NAD(P)H–dependent 
conversion of L-glutamate to pyrroline-5-carboxylate. The latter is converted 
into L-proline by pyrroline-5-carboxylase reductase in the cytosol. Proline can 
then enter mitochondria where it is oxidized back to pyrroline-5-carboxylate 
catalyzed by proline oxidase (POX). Reports have shown that catalytic cycling 
between pyrroline-5-carboxylate and proline can mediate redox transfers 
between mitochondria and cytosol and can regulate apoptosis in cells 
(225-226). The expression of POX has been found to be up-regulated in a 
human colon cancer cell line using adriamycin to initiate p53-dependent 
apoptosis. Increased reactive species were found by addition of proline in cells 
expressing POX, which induced apoptosis through the mitochondrial pathway. 
More recently, they found evidence suggesting that POX may also induce 
extrinsic apoptotic pathways (226). We saw an increase of delta 
1-pyrroline-5-carboxylate synthetase in MX cells, which may indicate that 
production of pyrroline-5-carboxylate is increased. As a hypothesis, the 
equilibrium reaction from proline to pyrroline-5-carboxylate may be reduced, 
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which will also repress POX expression as a feedback and thus reduce 
ROS-induced apoptosis in drug resistant cancer cells. But meanwhile, that 
means the increased pyrroline-5-carboxylate has to go through some other 
pathway to be used other than producing “toxic” proline. One possibility is that 
it is converted into L-ornithine and then arginine.  
Methylcrotonoyl-CoA carboxylase beta chain is an enzyme involved in 
leucine catabolism. Unfortunately, no literature could be found on the 
association between leucine catabolism and cancer or drug resistance. 
Transport 
The majority of mitochondrial proteins are encoded by nuclear genes and 
then targeted to the mitochondria by specific transport systems (227). GrpE 
protein homolog 1 cooperates with mitochondrial heat shock protein 70 (Hsp70) 
in the import of proteins from the cytoplasm. Hsp70 has been identified as a 
potent anti-apoptotic factor (228-230), which was suggested to prevent 
recruitment of procaspase-9 to the apoptosome complex or to inhibit 
caspase-3 activation, therefore hindering initiation of caspase cascade. A 
decrease abundance of GrpE protein homolog 1 was detected in MX cells from 
this research. How GrpE protein homolog 1 interacts with the cell death 
pathway to regulate response to chemotherapy needs further investigation.  
Of the twelve proteins exhibiting significant abundance changes, most of 
them are increased in the mitoxantrone-resistant MCF-7 cells compared to 
mitoxantrone-susceptible MCF-7 cells. As many of these proteins may block 
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one of the pathways leading to apoptosis induced by drugs as mentioned 
above, it is suggested here that anti-apoptotic factors play more important 
roles in drug resistance in MCF-7 cells rather than pro-apoptotic factors do. 
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Chapter 4: Conclusions 
 
Proteomics techniques enable comprehensive studies of proteins from 
complex biological systems. There has been an increased interest in 
mitochondrial proteomics over the last decade. The objectives of the present 
study were to evaluate a novel integrated proteomic strategy applicable to 
mitochondrial proteomics, as to identify mitochondrial proteins whose 
abundances are altered between drug-susceptible MCF-7 breast cancer cells 
and MCF-7 cells selected for resistance to mitoxantrone, in order to consider 
how these proteins contribute to drug resistance.  
Efficient separation techniques are required in mass spectrometry to 
provide global proteomic analysis. In this study, solution isoelectric focusing 
separation was applied to fractionate soluble mitochondrial proteins and thus 
reduce sample complexity. Each fraction was then further fractionated with 
reversed-phase capillary HPLC. This orthogonal two-dimensional separation 
technique is demonstrated here to have high reproducibility, resolution and 
flexible sample capacity. A total of 637 peptides corresponding to 278 proteins 
were identified. About 100 more proteins were detected by this method 
compared to the result with traditional 2D-gel performed also on the soluble 
mitochondrial protein sample in our lab (174). Among those, are many proteins 
with high pI values or hydrophobic character, which are usually excluded in 2D 
gel methods. In addition, it is estimated that half of the time was required for 
our shotgun method compared to the 2D-gel method, when we used the same 
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amount of sample. 
This shotgun method can be used in combination with stable isotope 
labeling techniques to determine changes in protein abundances between 
clinical or other limited samples. In the present study, we integrated 
enzyme-catalyzed 18O labeling with the shotgun method to study changes in 
mitochondrial proteins associated with drug resistance in human cancer cells. 
This combination appeared well-suited for sensitive quantitative comparison. 
Furthermore, reversed 18O labeling experiments were carried out to provide 
complementary pairs of isotopically labeled peptides. These were used to 
estimate the precision and dynamic range of the method, and to confirm the 
behavior of those proteins which were only detected in one cell line. The 
overall strategy identified twelve mitochondrial proteins with abundances 
altered significantly in drug resistant cells. These proteins are actively involved 
in apoptosis, oxidative phosphorylation, fatty acid metabolism and amino acid 
metabolism. None of them has been previously confirmed to contribute to drug 
resistance. Because we know that drug resistance in cancer is a multi-factorial 
process, we suggest that these proteins might play different but related roles. 
This study also provides a list of target proteins for further investigation, 
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